Title: SARS-CoV-2 infects human adipose tissue and elicits an inflammatory response

consistent with severe COVID-19

Authors:

Giovanny J. Martínez-Colón^{1†}, Kalani Ratnasiri^{2†}, Heping Chen¹, Sizun Jiang^{5,9}, Elizabeth Zanley¹, Arjun Rustagi¹, Renu Verma¹, Han Chen⁵, Jason R. Andrews¹, Kirsten D. Mertz¹⁰, Alexandar Tzankov⁸, Dan Azagury³, Jack Boyd⁴, Garry P. Nolan⁵, Christian M. Schürch⁷, Matthias S. Matter⁸, Catherine A. Blish^{1,2,6†*}, Tracey L. McLaughlin^{1†*}

Affiliations:

¹Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

²Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA

³Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA

⁴Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA

⁵Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

⁶Chan Zuckerberg Biohub, San Francisco, CA USA

⁷Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany

⁸Institute of Medical Genetics and Pathology, University Hospital of Basel, University of Basel, Basel, Switzerland

⁹Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA

¹⁰Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland

†Equal contributions

*Corresponding authors

Tracey L. McLaughlin

Department of Medicine, Division of Endocrinology, Gerontology, and Metabolism

300 Pasteur Dr,

Stanford, CA 94305

tmclaugh@stanford.edu

Catherine A. Blish

Department of Medicine, Division of Infectious Disease and Geographic Medicine

300 Pasteur Dr., Lane Building, L134

Stanford, CA 94305

cblish@stanford.edu

One sentence summary: Our work provides the first *in vivo* evidence of SARS-CoV-2 infection in human adipose tissue and describes the associated inflammation.

Abstract: The COVID-19 pandemic, caused by the viral pathogen SARS-CoV-2, has taken the lives of millions of individuals around the world. Obesity is associated with adverse COVID-19 outcomes, but the underlying mechanism is unknown. In this report, we demonstrate that human adipose tissue from multiple depots is permissive to SARS-CoV-2 infection and that infection elicits an inflammatory response, including the secretion of known inflammatory mediators of severe COVID-19. We identify two cellular targets of SARS-CoV-2 infection in adipose tissue: mature adipocytes and adipose tissue macrophages. Adipose tissue macrophage infection is largely restricted to a highly inflammatory subpopulation of macrophages, present at baseline, that is further activated in response to SARS-CoV-2 infection. Preadipocytes, while not infected, adopt a proinflammatory phenotype. We further demonstrate that SARS-CoV-2 RNA is detectable in adipocytes in COVID-19 autopsy cases and is associated with an inflammatory infiltrate. Collectively, our findings indicate that adipose tissue supports SARS-CoV-2 infection and pathogenic inflammation and may explain the link between obesity and severe COVID-19.

Main Text:

INTRODUCTION

The COVID-19 pandemic, caused by the viral pathogen SARS-CoV-2, has infected over 250 million people and taken the lives of over 4.5 million individuals globally as of October 2021. The clinical manifestations of COVID-19 range from asymptomatic infection, mild cold-like symptoms, to severe pulmonary and extrapulmonary manifestations characterized by extreme

inflammation and cytokine storm (1). Obesity has emerged as an independent risk factor for infection, severe disease, and mortality (2–6). While obesity is associated with comorbid conditions also related to severe COVID-19, the independent relative risk of obesity is higher than that of hypertension and type 2 diabetes (2, 5, 7). Further, obesity is a risk factor even in young adults and children who do not have other comorbid conditions (8). Several distinct mechanisms could underlie this association. Impaired respiratory mechanics may result from a heavy chest wall, airway resistance, and/or presence of obstructive sleep apnea (9). The metabolic milieu in obesity, particularly among individuals with insulin resistance, is characterized by systemic inflammation and hypercoagulability (10–12) and could thus stimulate a more robust inflammatory response to SARS-CoV-2. Impaired immune responses to viral infection are another possibility, as obese individuals exhibit altered immune cell profiles at baseline (13) and in response to influenza infection (7, 14).

Furthermore, a recent report demonstrated that SARS-CoV-2 can infect adipocytes *in vitro* (15); it is not known whether SARS-CoV-2 infects other adipose tissue-resident cells and/or drives an inflammatory response in adipose tissue. Other viruses have been shown to infect several cell types within adipose tissue, including adipocytes (influenza A virus), adipose-stromal cells (adenovirus 36, human cytomegalovirus), macrophages (simian immunodeficiency virus (SIV)), and T cells (human immunodeficiency virus (HIV))(16–19). Complex interactions between various cell types and adipocytes can drive significant inflammation, with reports of adipocyte-derived chemoattractants such as monocyte chemoattractant protein-1 (MCP-1) leading to macrophage infiltration (20), tumor necrosis factor alpha (TNF- α) activating nuclear factor kappa B (21, 22), and free fatty acids driving toll-like receptor 4-mediated inflammation and

insulin resistance (23). Thus, pronounced and/or prolonged SARS-CoV-2 viral replication and inflammation might occur in those with obesity and contribute to severe disease. Of particular concern is the possibility that viral infection of peri-organ fat could contribute to organ damage via inflammation and downstream processes such as extracellular matrix deposition/fibrosis, edema, impaired cellular function, endothelial dysfunction, and hypercoagulability (11, 13). To date, COVID-19 profiling studies have generally excluded adipose tissue from analyses; in other cases adipose tissue may have been lumped in with analyses of adjoining tissues (24, 25) These studies have shown that SARS-CoV-2 RNA and proteins are detected across numerous tissues, including the lung, brain, intestine, and pancreas (24, 26, 27). Thus, we undertook a study to test the hypothesis that SARS-CoV-2 infects cells within human adipose tissue and incites an inflammatory response. We harvested adipose tissue from multiple depots in uninfected obese humans for *in vitro* infection and obtained autopsy specimens of various adipose depots in individuals who died from COVID-19. Our results clearly show SARS-CoV-2 infection in macrophages and adipocytes from multiple adipose depots, with an attendant increase in inflammatory profile.

RESULTS

Establishment of a system to examine SARS-CoV-2 infection in human adipose tissue

To explore the ability of human adipose tissue to support SARS-CoV-2 infection and drive an inflammatory response, we recruited participants undergoing bariatric or cardiothoracic surgery. Freshly harvested tissue from the subcutaneous (SAT), visceral (VAT), pericardial (PAT) and epicardial (EAT) adipose tissue depots was subjected to collagenase digestion to separate

114 stromal-vascular cells (SVC) from mature adipocytes. Clinical characteristics are shown in table

115 S1.

116

117

Figure 1. Exposure of stromal vascular cells (SVC) from adipose tissue to SARS-CoV-2

supports infection of macrophages. (A) Sketch of workflow. SVC of human adipose tissue was isolated by collagenase digestion prior to viral infection. SVC was infected or left untreated

(mock) with SARS-CoV-2 (USA-WA1/2020) at a multiplicity of infection (MOI) of 1. (B) Relative gene expression of SARS-CoV-2 (N gene) obtained by 1-step RTqPCR at 24 hpi or mock infection (SAT, n=6; VAT, n=4). (C) Relative gene expression of SARS-CoV-2 (N gene) obtained by 1-step RTqPCR in cultures were treated with vehicle (DMSO) or 10 μ M remdesivir to inhibit viral replication and maintained for 24, 48, 72, and 96 hours before harvest. Relative expression was analyzed by $\Delta\Delta$ Ct method relative to a mock sample using 18S rRNA as a housekeeping gene. Each data point is an average of 3 technical replicates. (D) Frequency of SARS-CoV-2 infected cells based on SARS-CoV-2 N protein detection by flow cytometry of SAT (left, n=2) and VAT (right, n=2). Gating is detailed in supplemental figure 3. Statistical analysis: (A) paired, two-sided, student's t-test. **P<0.01, ***P<0.001. (B) Statistical analysis was performed with a two-way ANOVA, multiple comparisons using statistical hypothesis Sidak. *P<0.05. Data is presented as $\pm$ mean s.e.m. (A) Sketch was created with BioRender.

Human adipose tissue SVC supports SARS-CoV-2 infection

Freshly isolated SVC from human adipose tissue were exposed to SARS-CoV-2 (WA-01) at a multiplicity of infection (MOI) of 1 or mock-infected. Infection and replication were assessed by reverse transcription quantitative PCR (RTqPCR) for SARS-CoV-2 nucleocapsid (N) gene and by flow cytometry for SARS-CoV-2 N protein (Figure 1A). Both genomic (Fig. 1B) and subgenomic (fig. S1) viral RNA were detected in SARS-CoV-2 infected SVC from subcutaneous (n=6 Fig.1B; n=2 fig. S1), omental (n=4 Fig.1B; n=2 fig. S1), pericardial (n=1 fig. S1), and epicardial (n=1 fig. S1) adipose tissue. To confirm that *N-gene* detection represented active viral infection, we cultured infected cells in the presence of remdesivir, an inhibitor of the viral RNA-dependent RNA polymerase. We first confirmed the ability of remdesivir to inhibit viral RNA

accumulation in A549-ACE2 cells (fig. S2). In SARS-CoV-2-infected SVC from both SAT and VAT, we observed accumulation of *N-gene* copies over the course of 96 hours, indicating viral RNA replication (Fig. 1B). Importantly, remdesivir significantly reduced viral RNA levels at later time points in both tissue types (Fig. 1C). Together, these data indicate that SVC can support SARS-CoV-2 infection.

Next, to determine which of the SVC are infected, we performed flow cytometry to assess viral N protein expression in six major SVC types (dendritic cells, macrophages, B cells, T cells, preadipocytes, and endothelial cells) (Fig. 1A and fig. S3). In both SAT and VAT, SARS-CoV-2 N protein was primarily restricted to macrophages (defined as large granular CD45⁺CD14⁺CD11c⁻ cells) (Fig.1D). We next assessed the level of angiotensin-converting enzyme 2 (ACE-2), the cellular receptor for SARS-CoV-2 (28) in the SVC. ACE-2 protein expression was very limited in SVC, with no detectable expression in the VAT and very low-level expression on ~3% of SAT macrophages when compared to isotype control (fig. S4). In addition, we did not detect *ACE2* mRNA in any of the six samples collected from SAT, VAT, PAT or EAT (table S2). Thus, these data indicate that SARS-CoV-2 primarily infects macrophages in SVC and may enter through a non-canonical entry receptor.

Figure 2. A subset of macrophages is infected with SARS-CoV-2. (A) Schematic of experiment. The stromal vascular cells (SVC) were isolated from the SAT and VAT depots of three different participants and infected with either mock or SARS-CoV-2 (MOI of 1.0). Each sample was collected for scRNA-seq at 24 hpi. **(B-C)** UMAP representation of the SVC from all participants (n=3) across 198,759 cells, **(B)** colored by manually annotated cell type and **(C)** colored by infection and depot. **(D)** UMAP representation of all cells colored by SARS-CoV-2 cpm (log10). **(E)** Violin plot reveals the SARS-CoV-2 cpm values of all cells across SARS-CoV-

172 2 infected samples, showing only the 8 cell clusters with the highest composition of SARS-CoV-
173 2⁺ cells. Percentages above each cell type denote the percentage of cells within each cluster that
174 have over 10 SARS-CoV-2 reads. **(F)** UMAP projections of all macrophages from the scRNA-
175 seq dataset, colored by SARS-CoV-2 cpm (left), colored by CD68 expression (middle) and
176 colored by ACE2 expression (right). **(G)** Dotplot of the proportion of cells (dot size) in the
177 macrophage clusters split by infection condition expressing genes relevant for SARS-CoV-2
178 entry and antiviral defense, as well as SARS-CoV-2 cpm and macrophage cluster markers and
179 colored by scaled average expression. (A) Figure was created with BioRender.

Figure 3. The infected macrophage cluster is marked by increased chemokine expression.

(A) Volcano plot of the differentially expressed genes between macrophage clusters 2 (C2) and 12 (C12) across mock-infected samples. (B) Venn Diagram comparison of the significantly differentially expressed genes (DEGs) and their direction of change across C2 versus C12 in (1) mock-infected, (2) all SAT and (3) all VAT, and (4) SARS-CoV-2-infected conditions. (C)

Heatmap of the most significant DEGs between SARS-CoV-2+ versus bystander macrophages within C2. **(D)** Normalized enrichment scores of top Reactome pathways, using significant DEGs between SARS-CoV-2+ versus bystander C2 macrophages.

SARS-CoV-2 infects a distinct subset of macrophages

To comprehensively characterize the cells infected with SARS-CoV-2 in human adipose tissue, we performed single-cell RNA sequencing (scRNA-seq) of SARS-CoV-2 and mock-infected SVC isolated from both SAT and VAT from three bariatric surgery patients (Fig. 2A, table S3). We generated 198,759 single-cell expression profiles. After performing dimensionality reduction and Harmony batch integration (29), unbiased graph-based clustering resulted in 23 cell types (C0-C22) with marker genes that aligned with previous datasets and included three major cell groups: preadipocytes, immune cells, and endothelial cells (30, 31) (Fig. 2B, table S3, fig. S5). We saw the greatest heterogeneity across the preadipocyte population for which we identified 14 distinct clusters, each of which was labeled by its top two cluster defining genes. We similarly labeled two distinct macrophage clusters.

We detected SARS-CoV-2 at levels ranging up to 1079 transcripts per cell in a total of 8.8% of cells in the infected samples (fig. S6) and did not detect a single SARS-CoV-2 transcript in the mock-infected samples. The uniform manifold approximation and projection (UMAP) of SARS-CoV-2-exposed samples colored by viral counts-per-million (cpm) showed that macrophages contained the highest concentration of SARS-CoV-2 transcripts (Fig. 2D), with >85% of SARS-CoV-2 exposed C2-macrophages and >11% C12-macrophages containing more than ten viral transcripts (Fig. 2E). *ACE2* transcript was not detected in the SVC macrophages and therefore

could not explain the difference in infection levels between C2-macrophages and C12-macrophages (Fig. 2F, 2G). However, C2-macrophages expressed higher levels of *BSG*, *NRPI2*, *CTSB* and *CTSL* compared to C12-macrophages (Fig. 2G), all previously noted to be important to SARS-CoV-2 infection and viral processing (32–34). Our data suggest that these alternative entry receptors could contribute to SARS-CoV-2 entry into C2-macrophages.

To further evaluate how these two macrophage populations differ in SARS-CoV-2 susceptibility, we examined the most differentially expressed genes between the macrophage cluster that was highly enriched for SARS-CoV-2 reads (C2) versus the relatively uninfected cluster (C12) at baseline (mock-infected) and identified 1000 significant differentially expressed genes (Fig 3A, table S4). Notably, even in the mock condition, there was a significant upregulation of inflammation related transcripts within C2 compared to C12, and in particular, transcripts for numerous chemokine ligands (Fig. 3A, fig. S7B, table S6-7). Increased expression of *CCL8* and *CCL3*, chemokines involved in monocyte chemotaxis, highlight the potential of these infected cells to induce the infiltration of inflammatory monocytes and macrophages (35, 36). There was significant downregulation of 14 HLA genes across HLA Class I and Class II proteins, including *HLA-DRB1*, *HLA-DRA*, *HLA-DQB1*, and *HLA-DPB1*, in the C2-macrophages compared to C12-macrophages (Fig. 3A, table S4). Additionally, the C2-macrophage cluster demonstrated enrichment for transcripts associated with perivascular macrophages (PVM) including *CD163*, *SELENOP*, *MARCO* and *APOE* (Fig. 3B and (31, 37, 38)). In contrast, the relatively uninfected C12 demonstrated upregulation of genes relating to lipid metabolism and other markers of lipid-associated macrophages, including *FABP4*, *TGM2*, *GSN*, *TREM2*, *LPL* and *PGD*, suggesting that

this macrophage population might be implicated in lipid accumulation and trafficking and derived from metabolic activation (30, 31, 37, 39).

SARS-CoV-2 infection drives an inflammatory response in macrophages

As major differences between the macrophage clusters include markers of inflammation (i.e. *IL1B*, *CXCL8*, *CCLs*) (Fig. 3A-B), this raises the possibility that *in vitro* SARS-CoV-2 infection drives the formation of the C2-macrophage cluster. However, this cluster is present in mock-infected samples, and both SARS-CoV-2-infected and mock-infected samples displayed a similar array of differentially expressed genes between these clusters (Fig. 3B, fig. S7A), indicating that this inflammatory C2-macrophage cluster is naturally present in the SVC of adipose tissue and is more susceptible to infection *in vitro*.

To explore the cell-intrinsic effects of infection, we compared the transcriptional profiles of C2-macrophages that did (infected) or did not (bystander) contain SARS-CoV-2 transcripts within the infected cultures (fig. S7C, Fig. 3C, table S5). Though there were baseline differences in gene expression between participants, several genes strongly distinguished SARS-CoV-2⁺ C2 cells from bystander C2 cells by hierarchical clustering (Fig. 3C); many of these genes also distinguish C2-macrophages from C12-macrophages (fig. S7D). For instance, *CCL4*, *CCL8*, and *CCL3* genes were significantly enriched in the infected cells within C2, and *LYZ* and *THBS1* were significantly downregulated within the infected cells. As these genes contributed to defining the C2 population from C12 cells, this result suggests that SARS-CoV-2 infection may drive C2 features to further extremes. Pathway analysis of significant DEGs between the SARS-CoV-2⁺ cells versus bystanders highlights the enrichment of pathways associated with IL-10

signaling (Fig. 3D, table S8), which is consistent with upregulation of this pathway in monocytes of severe COVID-19 patients (40). Chemokine and other innate immune system-associated pathways are also highly enriched in infected cells (Fig. 3D), which has been previously demonstrated (41). Interestingly, there is a reduced enrichment in pathways related to translation machinery of the host, which is supported by SARS-CoV-2 studies suggesting that SARS-CoV-2 infection has the ability to reshape translation, splicing, protein homeostasis and nucleic acid metabolism pathways (42, 43). Thus, the macrophages with detectable SARS-CoV-2 RNA display a dramatic transcriptional response with upregulation of inflammatory pathways.

Figure 4. Preadipocytes respond to SARS-CoV-2 exposure. (A, B) UMAP embedding of all preadipocytes (n=140,867) colored by (A) cluster and (B) sample and infection type. (C) Cell fraction bar plot clustered by sample and infection type within each cluster. (D) Feature plots depicting expression of selected markers associated with preadipocyte cell states, cell types and antiviral genes. (E) Box plots of average cytokine (top) and ISG- (bottom) module scores across the preadipocytes of each participant and depot in both mock and SARS-CoV-2 infection conditions. (F) Reactome pathway analysis was performed on the significant DEGs by

participant and cluster within SAT. Pathways that were represented and significant in at least four of the participant-cluster subsets were included. Pathways clustered by Euclidean distance (tree not shown) and split by the two major subtrees.

Adipocyte progenitors demonstrate an inflammatory response to SARS-CoV-2 infection of macrophages

Given that exposure of preadipocytes to inflammatory cytokines such as TNF- α or IL-6 can alter their phenotype (31, 44), we next evaluated whether SARS-CoV-2 infection of SVC led to a bystander activation of preadipocytes. We embedded only preadipocytes and used unsupervised clustering to identify 17 unique clusters (P0-P16) (Fig. 4A-C, fig. S8A, table S9). Notably, SAT and VAT preadipocytes were highly transcriptionally unique, with 11/17 clusters each composed of over 75% of cells derived from only one depot. Overall, there was not a dramatic shift in cluster composition of SARS-CoV-2-infected and mock-infected samples, except for cluster P15 which was highly enriched with preadipocytes from SARS-CoV-2-infected SAT (Fig. 4C). This cluster was highly inflammatory, with dramatic upregulation of two antiviral interferon stimulated genes (ISGs), *IFIT1* and *ISG15* (fig. S8A), suggesting a relatively robust response to infection in the SAT. The remaining clusters were distinguished by several unique DEGs (fig. S8A, table S9), including *CXCL14* and *APOD* in cluster P9, indicating enrichment with adipocyte stem cells (ASCs) (30, 31, 45); *KRT18* and *MSLN* in clusters P1 and P4 indicating enrichment with mesothelial cells in VAT only, as previously reported (30, 45, 46). Further, VAT-predominant clusters demonstrated higher levels of *IFI27* (a marker of SARS-CoV-2 infection in the blood) than other clusters while *IL-6* expression was high across all

preadipocytes in mock-conditions, highlighting the highly inflammatory nature of preadipocytes at baseline.

To more globally investigate the effects of SARS-CoV-2 infection on SAT and VAT preadipocytes, we looked at the total number of DEGs upon SARS-CoV-2 infection across each participant's SAT and VAT and noticed that for each participant, the SAT had a higher number of DEGs than the paired VAT sample, suggesting that the SAT had a stronger transcriptional response than VAT (fig. S8B). We then used known ISGs and cytokine genes to generate ISG and cytokine gene scores for each participant, infection condition and depot (Fig. 4E, table S14). Infection induced both ISGs and cytokines, but SAT demonstrated a greater increase in ISG and cytokine responses than did VAT. These data also revealed that in these three participants, the VAT depot has a higher baseline cytokine expression that is further increased upon SARS-CoV-2 exposure (Fig. 4D, fig. S9A).

Next, we wanted to see whether particular preadipocyte clusters within the SAT and VAT showed a stronger response to SARS-CoV-2 exposure. We employed perturbation analysis previously described (47, 48) to identify which cluster within each depot and participant demonstrated the strongest changes across infection conditions (fig. S8C, S8D). Interestingly, across both depots, the ASC-like cluster, P9, along with nearby clusters, P16 and P12, showed the lowest perturbation relative to other clusters. While donors varied in their most highly perturbed clusters, this analysis demonstrated that SAT showed consistently stronger perturbation than VAT upon SARS-CoV-2 infection. Therefore, we then focused on the SAT to understand the particular pathways by cluster that contribute to the overall inflammatory

response in the depot. To do this, we identified the DEGs between SARS-CoV-2 exposed versus mock preadipocytes by cluster, depot, and participant and employed gene set enrichment analysis using the Reactome database to identify relevant pathways to understand the response within each participant and each cluster (Fig. 4F, table S10-13). Clusters P5 and P2 consistently showed transcriptional enrichment for genes relevant to an immune response, more specifically related to cytokine signaling. Additionally, pathway analysis by cluster and participant shows that in participant 1 and 2, which seemed to have a more dramatic response to SARS-CoV-2 infection, we see most of the adipose clusters showing enrichment in responses relevant to the immune system. Participant 3 only had 2/17 clusters revealing enrichment for immune-related pathways. Negatively enriched pathways relate to viral transcription and translation pathways which suggests that preadipocytes are also expressing genes to suppress viral production. A similar analysis was also performed on the VAT depot which demonstrated a similar enrichment for immune response pathways across preadipocyte clusters, with participant 1 eliciting more dramatic changes across their preadipocyte compartment (fig. S8D). Overall, these data indicate that SARS-CoV-2 infection within the SVC macrophages drives inflammatory responses in the neighboring preadipocyte cells.

Table 1: 80-plex Luminex analysis of Stromal Vascular Compartment from human adipose tissue

Analyte	Category	Results				Known role in COVID-19	References
		SAT (n=8)		VAT (n=6)			
		Mean	p value/ q	Mean	p value/ q		
		Fold change	value	Fold change	value		
IP-10	Chemokine	19.3	0.01/0.06	17.04	0.03/0.18	Elevated in acute cases and critically ill patients; associated with disease severity and ICU admission; predictor of disease progression; biomarker of impaired T cell response in acute infection	(49–57)
MCP2		0.74	0.02/0.1	1.12	0.03/0.18	Elevated in critically ill patients	(56)
MCP3		1.32	0.04/0.2	0.97	0.84/1	Elevated in serum and blood; associated with disease severity and predictor of disease progression	(50, 53–56)
CXCL13		1.19	0.02/0.1	0.96	0.63/0.98	Elevated in serum	(58)
CCL27		0.99	0.74/0.97	1.12	0.03/0.18	Secreted by HeLa cells in response to SARS-CoV-2’s ORF7a	(59)
PDGFAA	Growth Factor	5.41	0.01/0.06	4.06	0.03/0.18	Associated with severe disease and ICU admission	(51)
PDGFAB /BB		1.12	0.01/0.06	1.11	0.09/0.36	Elevated in serum and associated with ICU admission	(51, 55)
VEGF		3.81	0.01/0.06	2.52	0.03/0.18	Elevated in serum; role in COVID-19 brain inflammation	(55, 60)

MCSF		2.57	0.01/0.06	2.07	0.03/0.18	Elevated in serum	(52)
GM-CSF		1.81	0.08/0.31	1.49	0.03/0.18	Elevated in serum, including in mechanically ventilated patients	(52–55)
LIF		0.57	0.01/0.06	1.44	0.03/0.18	Proposed to treat COVID-19 patients by decreasing IL-6	(61)
TGF- α		2.01	0.01/0.06	1.81	0.03/0.18	Not known role	
IL-4	Th2	1.96	0.01/0.06	2.02	0.03/0.18	Elevated in serum	(51, 55)
IL-13	Cytokines	1.13	0.08/0.31	1.22	0.03/0.18	Elevated in serum	(51)
MIF	Inflammat	12.16	0.01/0.06	10.81	0.03/0.18	Elevated in critically ill patients	(62)
IL-21	ory cytokines	1.08	0.01/0.06	0.92	0.25/0.69	Elevated in serum compared to non-COVID-19 pneumonia patients	(63)
TNF- β		1.17	0.01/0.06	1.23	0.03/0.18	Not Known role	
sICAM1	Cell adhesion	0.87	0.04/0.2	0.94	1/1	Elevated in non-survivor compared to survivor	(64)
SCF	HRC	0.9	0.02/0.13	1.08	0.03/0.18	Not known role	

Abbreviations: Interleukin (IL), Interferon gamma inducible protein 10 (IP-10), Macrophage colony stimulation factor (MCSF), Platelet-derived growth factors (PDGF), Transforming growth factor alpha (TGF α), Tumor necrosis factor beta (TNF- β), Vascular endothelial growth factor (VEGF), Macrophage migration inhibitory factor (MIF), Granulocyte colony stimulation factor (GM-CSF), Leukemia inhibitory factor (LIF), Monocyte chemoattractant protein 2 (MCP2), C-X-C motif ligand (CXCL), Stem cell factor (SCF), C-C motif chemokine ligand (CCL), Soluble intercellular adhesion molecule-1 (sICAM1), Hematopoiesis regulatory cytokine (HRC)

Statistical analysis: Wilcoxon rank test corrected for multiple testing by the Benjamini-Hochberg method. False discovery rate of 10%. Numbers were rounded to their significant digits.

Table 1. 80-plex Luminex analysis of stromal vascular cells from human adipose tissue

exposed to SARS-CoV-2. Table summarizing results of 80-plex Luminex assay performed in supernatants of SVC (SAT, n=8; VAT, n=6) cultures that were infected with SARS-CoV-2 or mock-infected for 24 hours. First column shows analytes of interest. Second column categorizes analytes in either chemokine, growth factor, Th2 cytokine, inflammatory cytokine, cell adhesion molecule, or hematopoiesis regulatory cytokine. Columns 3 to 6 summarizes statistical results splitted by mean fold change and p and q (Adjusted p value) value obtained from Wilcoxon signed rank test. Columns 7 and 8 summarizes the known role of each analyte in COVID-19. Bottom of the table contains abbreviations and descriptions of statistics.

SARS-CoV-2 infection of SVC induces inflammation

To better understand the impact of SARS-CoV-2-mediated infection on inflammatory responses within the SVC, we measured the relative gene expression of *IL-6* by RTqPCR (fig. S11A) in SARS-CoV-2 infected versus mock-infected SVC. We selected *IL-6* due to its high presence in severe cases of COVID-19 (65), its association with low-grade inflammation in obese individuals (66), and its likely role in COVID-19 immunopathogenesis (67). SARS-CoV-2-infection drove significantly increased *IL-6* expression in SAT (n=6) (fig. S11A). *IL-6* transcripts were also increased in VAT (n=6), but the change was not statistically significant (fig. S11A). Additionally, we measured gene expression of five interferon-related genes (*IFNA1*, *IFNB1*, *ISG15*, *IFI27*, and *IER3*) in SAT and VAT infected with SARS-CoV-2 over a period of 96 hpi (fig. S10). We identified increased expression of *IFNA1*, *IFNB1*, and *ISG15* as viral RNA accumulated in both SAT and VAT demonstrating induction of antiviral response (fig. S10).

To better understand the impact of SARS-CoV-2 infection on inflammatory responses within the SVC, we tested supernatants from infected versus mock-infected cultures for protein expression of various secreted inflammatory markers by Luminex. As compared to mock infection, SARS-CoV-2 infection of SAT and VAT resulted in upregulation of several chemokines, cytokines, growth factors, and other inflammatory mediators (Table 1). In both SAT and VAT, the elevated production of IP-10 is particularly noteworthy as this cytokine has been reported to be elevated in the serum of critically ill COVID-19 patients (49). Additionally, we found the platelet-derived growth factor (PDGF)-AA, and AB/BB (PDGFAB/BB) together with the type 2 (TH2) immune factor interleukin-4 (IL-4) to be elevated in SARS-CoV-2 infected SAT. Similarly, PDGF-AA, IL-4, and IL-13 (another TH2 factor) are elevated in the SARS-CoV-2 infected VAT. Together, these data suggest that adipose tissue could contribute to the secretion of the cytokines and vascular factors in the setting of COVID-19 infection.

Figure 5. Mature and *in vitro* differentiated adipocytes support SARS-CoV-2 infection.

Mature adipocytes (MA) of human adipose tissue were isolated by collagenase digestion prior to viral infection. MA were infected or left untreated (mock) for 24 hours with SARS-COV-2 (USA-WA1/2020) at a MOI:1. (A) Measurements of genomic (gRNA) and subgenomic (sgRNA) SARS-CoV-2 genome copy numbers infected MA from subcutaneous (left; n=3) and visceral (right; n=2 omentum; n=1 epicardial; n=1 pericardial) adipose tissue obtained by absolute gene quantification using 1-step RTqPCR TaqManTM and reported as fold change of infected to mock). (B) Relative gene expression of *N* gene in adipocytes differentiated *in vitro*

from pericardial preadipocytes using adipocyte differentiation media for 0, 3, 6, and 13 days before left untreated or infected with SARS-CoV-2 at a MOI:1. Results were obtained by 1-step RTqPCR and analyzed by $\Delta\Delta C_t$ method using 18s as a housekeeping gene. (C) Adipocytes differentiated *in vitro* from preadipocytes obtained from pericardial adipose tissue were infected or mock infected with SARS-COV-2 (USA-WA1/2020) at a MOI of 1 for 1 hour, followed by washing and removing the virus and replacing with media treated with vehicle (DMSO) or 10 μ M remdesivir to inhibit viral replication. Cultures were maintained for 24, 48, 72, and 96 hpi, after which gene expression was obtained by 1-step RTqPCR for the *N* gene. Relative expression was analyzed by $\Delta\Delta C_t$ method relative to the mock sample. (C) Each data point is an average of 3 technical replicates and are presented as $\pm$ mean s.e.m.

Mature and *in vitro* differentiated adipocytes support SARS-CoV-2 infection

We next explored whether mature adipocytes could support SARS-CoV-2 infection. Mature adipocytes were infected with SARS-CoV-2 or mock infected. We detected both genomic and subgenomic SARS-CoV-2 (*N gene*) in infected mature adipocytes from both SAT (n=3) and VAT (n=2 omentum; n=1 EAT; n=1 PAT) by absolute gene quantification 24 hpi (Fig. 5A). We also measured secreted inflammatory mediators by Luminex in these infected mature fat samples (fig. S9A, S9B). There was a trend for increased secretion of VEGF, PDGFAA, PDGFAB/BB and IP-10 upon infection, but no significant differences in cytokines levels (fig. S9A-B).

We next evaluated infection in differentiated preadipocytes (68). As a control of successful differentiation, we confirmed an increase in gene expression of fatty acid binding protein 4 (*FABP4*) (69) on differentiated adipocytes (table S2B). *ACE2* expression was not detected in

undifferentiated preadipocytes (day 0) but was detected by day 3 in SAT, VAT, and PAT (table S2B). Adipocytes differentiated from PAT were infected at days 3, 6, and 13 of differentiation. We detected SARS-CoV-2 (*N gene*) at 24 hpi in all differentiated adipocytes (Fig. 5B). Adipocytes differentiated from SAT had detectable genomic and subgenomic SARS-CoV-2 RNA detected 24hpi on adipocytes at day 0 and day 3 of differentiation (fig. S9C-D). To determine whether SARS-CoV-2 can replicate in differentiated adipocytes, we infected day 13 differentiated adipocytes, and cultured them with either vehicle or remdesivir. We observed increased viral reads in differentiated adipocytes by 72 hpi; this viral RNA replication was partially inhibited by remdesivir (Fig. 5C). These results show that both freshly isolated mature adipocytes and adipocytes differentiated in culture can be infected by SARS-CoV-2 and represent an additional replication site.

Figure 6. SARS-CoV-2 RNA and immune infiltration are present in adipose tissue of autopsy samples from COVID-19 patients. RNA *in situ* hybridization (ISH) on epicardial fat from heart autopsies from patients (Top, autopsy #9; Bottom, #10) who succumbed to COVID-19. Assays were performed using probes against SARS-CoV-2 Spike mRNA. Red arrowheads

show ISH positive signals and blue arrows show inflammatory cells. **(A and C)** Overview of the heart tissue section (2mm), and **(B and D)** magnified view (20um) of the represented region. **(E)** Interface of epicardial fat and myocardium (50um). Note the inflammatory infiltration (blue arrows) only in the epicardial fat. Image has been rotated 90°.

SARS-CoV-2 is detected in the adipose tissue from deceased COVID-19 patients.

We next sought to find evidence for SARS-CoV-2 infection of adipose tissue *in vivo*. We performed RTqPCR for SARS-CoV-2 genes in lung, fat, heart, and kidney tissue samples in a cohort of eight COVID-19 autopsy cases (Table 2; autopsy # 1-8). Studies assessing SARS-CoV-2 levels in the lungs and heart of several subjects here have been previously published (70–72). In addition to detecting SARS-CoV-2 in the lung and heart, we also detected SARS-CoV-2 in epicardial, visceral, and subcutaneous adipose tissue and kidney (Table 2). As expected, SARS-CoV-2 detection was highest in the lung (mean Ct=25). Interestingly, it was followed by adipose tissue (mean Ct=33), heart (mean Ct=34) and kidney (mean Ct=34). In addition, we performed RNA *in situ* hybridization (ISH) on epicardial fat (Fig. 6). We detected SARS-CoV-2 in the cytoplasm of adipocytes in the epicardium and not in immune cells or myocardium (Fig. 6A-D). Mononuclear cell infiltration, mainly consisting of lymphocytes, is observed in areas showing positive SARS-CoV-2 signal in epicardium (Fig. 6A-E). Our results provide evidence of SARS-CoV-2 detection in the adipose tissue of COVID-19 autopsies, indicating that adipose tissue can harbor SARS-CoV-2 infection and contribute to pathogenic inflammation.

Table 2: Evidence of SARS-CoV-2 detection in adipose tissue from deceased individual

Autopsy #	Sex	Age (years)	Ethnicity	BMI (kg/m ²)	DHBD (Days)	Comorbidities	RTqPCR for SARS-CoV-2 (Ct values)				Type of adipose analyzed
							Lung	Heart	Kidney	Adipose	
1	F	84	C	24	12	CAD, HTN, metastatic lung CA, T2D, AKI, dementia	UD	UD	UD	UD	Epicardial
2	M	85	C	26	5	HTN, dyslipidemia, T2D, prostate CA in remission, OSA, cirrhosis, leukemia in remission	23	33	33	33	Visceral
3	F	81	C	26	4	CAD, HTN, PAD, AKI, former smoker	22	34	36	36	Visceral
4	M	71	C	24	NH	PAD, CAD, valvular heart disease, AKI	27	33	UD	33	Visceral
5	M	65	C	26	8	Dyslipidemia, CAD, COPD, HTN, T2D, OSA, AKI	23	34	34	33	Epicardial
6	M	89	C	N/A	5	CAD, cardiomyopathy, dyslipidemia, T2D,	21	31	N/A	28	Epicardial

						OSA, former smoker, COPD					
7	M	85	N/A	30	5	Former smoker, HTN, cardiomyopathy, COPD, AKI, dementia	26	35	UD	34	Subcutan eous
8	M	58	C	47	7	Former smoker, HTN, obesity, CAD, CHF, AKI	35	37	33	36	Subcutan eous
9*	F	78	C	35.2	NH	obesity, AV-block III with pacemaker, HTN, cerebellar infarcts	N/A	N/A	N/A	34	Epicardia l
10*	F	87	C	N/A	1	Dementia, obesity, CAD, HTN, T2D	N/A	N/A	N/A	32	Epicardia l

Note: All Ct values presented are an average of *ORF1ab*, *S*, and *N* genes. All heart RNA samples were collected from a mixture of myocardium and epicardium. Any Ct value below 37 was considered a true SARS-CoV-2 signal. Autopsies labeled with (*) means cases were from Tübingen and not part of the Basel cohort.

Abbreviations: not available (N/A), undetected (UD), threshold cycles (Ct), open reading frame 1ab (ORF1ab), spike (S), nucleocapsid (N), days of hospitalization before death (DHBD), not hospitalized (NH), not available (N/A), Caucasian (C), male (M), female (F), body mass index (BMI), coronary artery disease (CAD), hypertension (HTN), type 2 diabetes mellitus (T2D), cancer (CA), acute renal insufficiency (AKI), obstructive sleep apnea (OSA), peripheral artery disease (PAD), chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF).

Table 2. Evidence of SARS-CoV-2 detection in adipose tissue from deceased individuals.

Table summarizing SARS-CoV-2 PCR signals from 8 autopsy cases, seven of them from patients deceased from COVID-19. All threshold cycles (Ct) presented are an average of three

SARS-CoV-2 gene sequences for open reading frame 1ab (*ORF1ab*), spike (*S*), and nucleocapsid (*N*). RNA was isolated from either epicardial, visceral, or subcutaneous fat. Heart RNA samples were collected from a mixture of myocardium and epicardium. Samples not presented in this study were marked as not available “N/A”. When the PCR signal was undetected, the sample was marked as “UD”.

DISCUSSION

Here, we report that SARS-CoV-2 infects human adipose tissue in COVID-19 patients and *in vitro*. Significantly extending a prior report that human adipocytes can be infected *in vitro* (15), we identify both tissue-resident macrophages and mature adipocytes as target cells for SARS-CoV-2 infection (16, 17, 19). Additionally, this study reveals that *in vitro* infection leads to activation of inflammatory pathways in macrophage and preadipocytes and the secretion of inflammatory factors associated with severe COVID-19. Finally, we provide the first evidence that this may be relevant to disease pathogenesis in humans *in vivo*, as we detected SARS-CoV-2 RNA in VAT, EAT, and SAT of COVID-19 autopsies. We also demonstrate histologic evidence of inflammation adjacent to viral signals in adipose tissue in an autopsy sample. Together, this in-depth analysis of adipose susceptibility and inflammatory response to SARS-CoV-2 infection suggests that adipose tissue may serve as a potential reservoir for SARS-CoV-2 and potentiator of systemic and regional inflammation, possibly contributing to severe clinical disease in obese individuals infected with SARS-CoV-2.

One of our most intriguing findings was that SARS-CoV-2 infection of adipose SVC was primarily restricted to just one of two macrophage clusters. The two macrophage populations

were defined as: C2-macrophages, an inflammatory cluster with *IL1B* and *CCL3* as its most distinguishing transcripts, and C12-macrophages, characterized by significant enrichment of HLA class II transcripts and *LYZ* and alarmin *S100A8* expression. C2-macrophages were predominately infected, with over 85% of C2 cells within infected SVC carrying SARS-CoV-2 transcripts. These two clusters do not fall into a classical M1 and M2 classification: instead, macrophages activated in response to adipose tissue signals may exhibit a unique phenotype (39, 73). The C2 macrophages express transcripts characteristic of PVMs, which have been previously described in adipose tissue (31) and are highly phagocytic (74). PVMs can become virally infected: in the brain, PVMs have been shown to become infected by HIV and SIV (38, 75). Interestingly, SARS-CoV-2 infection further drives the C2/C12 dichotomy as chemokine markers are further upregulated while *LYZ* and HLA expression is further downregulated in infected SARS-CoV-2 transcript-containing C2 cells versus their bystander counterparts. *LYZ* is of particular interest as prior studies have shown that lysozyme can play a role in antiviral activity (76–78), which suggests that low lysozyme levels (as found in the susceptible C2 cluster) may be advantageous for the virus. For example, influenza infection reduces lysozyme secretion in neutrophils (79) and the combination of lysozyme and lactoferrin therapy reduces Bovine viral diarrhoea virus titers *in vitro* (76, 78). This data suggests that lysozyme therapy could reduce SARS-CoV-2 levels in the adipose tissue. We also observed significant reduction in HLA Class I and II genes relevant to antigen presentation in the infected C2-macrophages cluster, consistent with findings in blood monocytes in severe COVID-19 disease (80, 81) which reduces immune surveillance and targeting of infected host cells, another infection-induced change which could be advantageous for virus propagation. Together, these data highlight the pivotal role macrophages may play in disease pathogenesis and the need for a better

understanding of how tissue macrophages at different sites are infected by and control SARS-CoV-2 infection.

The role of macrophages in supporting SARS-CoV-2 replication has been a subject of significant interest as there is no consensus about whether macrophages support viral replication. SARS-CoV-2 and the related coronaviruses SARS-CoV-1 and MERS can enter macrophages (82–84), but the downstream effects remain unclear. One study shows that neither MERS-CoV nor SARS-CoV-1 can replicate in human macrophages *in vitro* (82), another found that MERS-CoV but not SARS-CoV-1 can replicate within human monocyte-derived macrophages (83), and yet another study demonstrated abortive SARS-CoV-1 infection of human macrophages (84). For SARS-CoV-2, a recent study reported that the virus fails to replicate or induce an inflammatory response in human monocyte-derived macrophages *in vitro* (85), while another study showed that the SARS-CoV-2 spike protein can induce macrophage activation in murine cells (86). Importantly, these studies focused on blood-derived macrophages, and tissue-resident macrophages may have different properties. SARS-CoV-2 has been detected in human alveolar macrophages COVID-19 patients (87). While it is possible that infection in adipose tissue macrophages is abortive, two lines of evidence suggest that this infection is productive. First, we detected both genomic RNA and positive sense sgRNA, an intermediate RNA made during viral replication (88); however, these data should be interpreted with caution as sgRNAs can be quite stable and therefore may not fully reflect active replication (89, 90). Second, we observed increased viral RNA accumulation over time in SVC infections, suggestive of viral replication, which was decreased by remdesivir, an inhibitor of the viral RNA-dependent RNA polymerase. Interestingly, we also observed enrichment in inflammatory pathways and a reduction in host

translation pathways specifically in infected macrophages, indicative of viral hijacking of host translation (91). Such suppression of host translation has been also noted in SARS-CoV-1 infection: the NSP1 protein of SARS-CoV-1 suppresses host translation and gene expression, including those of type I interferons (43). Together, these data highlight the dramatic effects of SARS-CoV-2 infection on macrophages.

We also found that SARS-CoV-2 can infect human adipocytes both *in vitro* and *in vivo*. Previously, researchers demonstrated that SARS-CoV-2 is detectable in adipose tissue of SARS-CoV-2-infected hamsters, and that human adipocytes derived from breast tissue can support infection *in vitro* (15). Here we demonstrate infection in multiple different adipose depots, including critical peri-organ depots. We show this through (1) detection of both genomic and subgenomic SARS-CoV-2 *N gene* expression in infected mature adipocytes and (2) infected differentiated preadipocytes, (3) demonstration of a reduction in SARS-CoV-2 viral load in differentiated preadipocytes post-infection in response to remdesivir treatment, and (4) histology showing SARS-CoV-2 in adipocytes in a COVID-19 autopsy. This data adds to a growing body of evidence that adipose tissue can serve as a reservoir for RNA viruses including influenza A virus and HIV (16, 17, 19). Collectively, this data suggests that adipose tissue may serve as a reservoir for SARS-CoV-2.

Our data show that preadipocytes adopted proinflammatory phenotypes following SARS-CoV-2 infection of SVC, despite not being infected themselves. We noted 17 different preadipocyte clusters that varied in their representation among VAT and SAT depots. Interestingly, we found that adipocyte stem cell-like clusters demonstrated more subdued transcriptional changes in

response to infection compared to other clusters across depots and participants. Pathways upregulated across various preadipocyte clusters in response to infection included interferon and interleukin signaling, both of which are important to controlling viral infection. Previous reports have demonstrated that IL-6 and TNF- α cytokine exposure can impair preadipocyte differentiation and lipid accumulation, instead promoting the transition of preadipocytes towards an inflammatory state (44, 92). Thus, the SARS-CoV-2 infection of adipose tissue could drive a proinflammatory cascade promoted by preadipocyte activation. Interestingly, SAT preadipocytes had a more dramatic inflammatory response than VAT preadipocytes. This was surprising because several studies have pointed to the VAT being a better predictor of COVID-19 severity than the SAT (93–95). For example, a recent single-center cohort study demonstrated that increased VAT thickness and lower SAT thickness increased the risk of COVID-19 ICU admission, independent of BMI (95). While bulk transcriptomic data collected from *in vivo* SARS-CoV-2 infection of hamsters concluded that VAT had a stronger antiviral response than SAT, this study included only mature adipocytes and studied the response 48 hpi (15). While our human data similarly demonstrates higher cytokine expression of VAT preadipocytes at baseline, it also suggests that the SAT preadipocytes might play an underappreciated role early upon infection by driving an increased inflammatory response.

A significant finding of our study is the dramatic inflammatory response following SARS-CoV-2 infection of adipose tissue, particularly within the SVC. Across multiple experiments, at both the RNA and protein level, we saw increased expression of cytokines, ISGs and other molecules related to inflammation and antiviral pathways 24 hours after SVC infection. Many of the molecules we found upregulated upon SARS-CoV-2 infection are associated with COVID-19

severity: IP-10, PDGFAA, PDGFAB/BB, IL-4, and MCSF all have been reported to be elevated in the serum of critically ill COVID-19 patients (49, 51, 52), MIF has been described as a predictor of poor outcome on mechanically ventilated COVID-19 patients (62), and VEGF may play a crucial role in COVID-19 related brain inflammation (60). Further, we detected increased type I interferon transcripts and *ISG15* in SVC of both SAT and VAT 72 and 96 hpi, indicative of a persistent antiviral response during viral replication. While significantly less dramatic, we also saw trends for increased inflammatory cytokine and chemokines following infection of mature adipocytes. Notably, we observed both induction of transcripts (CCL8 and CCL3) and demonstrated secretion of chemokines (MCP2 and MCP3) in infected SVC cultures that can attract macrophages. This is entirely consistent with our autopsy finding of an inflammatory infiltrate associated with SARS-CoV-2⁺ cells and suggests that the antiviral response may be dragging more susceptible macrophages to the site of infection. These data suggest that targeted inhibition of inflammation in the adipose tissue could improve outcomes in COVID-19 subjects. In fact, therapeutics targeting inflammation of the adipose tissue during obesity-induced inflammation have been proposed as a treatment for metabolic disease (96). For instance, salicylate, a cyclooxygenase inhibitor, reduces inflammation of the adipose tissue in obese individuals and has been proposed as a therapeutic strategy in COVID-19 patients due to its anti-inflammatory properties and antiviral activity against both DNA and RNA viruses (97–103). Therefore, drugs reducing inflammation of the adipose tissue in obese individuals should be further explored in COVID-19 subjects.

The mechanism(s) of viral entry into adipocytes and SVC macrophages remain unclear but may not be through the canonical ACE2 receptor. While *ACE2* mRNA expression has been reported

in adipose tissue, (113) and its level is affected by diet and obesity (114), we detected no ACE2 protein in SVC from VAT, and almost no expression in SAT. We could not detect *ACE2* gene expression in SVC from either SAT or VAT, either by RTqPCR with primers validated on kidney tissue or by scRNA-seq. Similarly, we did not detect *ACE2* in mature adipocytes, though we did identify upregulation of *ACE2* transcripts during *in vitro* differentiation of preadipocytes. Another recent study also detected higher levels of *NRPI* and *FURIN* (two other proposed SARS-CoV-2 viral entry factors) compared to *ACE2* and *TMPRSS2* in murine and human adipocytes (15). In both macrophages and adipocytes, entry could occur via use of an alternate entry receptor. Genome-scale CRISPR loss-of-function screens in susceptible human cells have identified multiple SARS-CoV-2 entry factors in addition to *ACE2* (115). Alternative entry receptors reported include CD147, Neuropilin-1, Dipeptidyl peptidase 4 (DPP4), alanyl aminopeptidase (ANPEP), glutamyl aminopeptidase (ENPEP), and angiotensin II receptor type 2 (AGTR2) (104, 105). In macrophages, entry could also occur via phagocytosis of viral particles, phagocytosis of infected cells, or, if antibodies were present, via antibody-dependent entry. Elucidating the entry mechanisms will be an important area of future investigation given its implications for disease pathogenesis. For example, Neuropilin-1 has may mediate entry into neural cells and play a role in neurologic manifestations of COVID-19 (106), and yet antibody therapies that only block interactions with ACE2 may not block such entry if it is relevant *in vivo*.

Our study has several limitations. Our numbers of replicates were limited for some assays, such as the evaluation of cytokine secretion following infection of mature adipocytes. Nonetheless, we observed significant indications of inflammatory responses. It is possible that we were unable to

fully wash input virus following infection of mature adipocytes due to the high lipid content, size, and fragility of the cells, falsely increasing the viral signal. However, our detection of sgRNA, the time-dependent increase in viral RNA accumulation that was inhibited by remdesivir, and the detection of SARS-CoV-2 RNA in autopsy samples all provide orthogonal support for true infection of adipocytes. Our autopsy studies were limited in number, and we were only able to perform confirmatory ISH on epicardium, not in the subcutaneous, omental, or pericardial fat due to limited autopsy tissue availability. All experiments were performed with the WA-01 strain of SARS-CoV-2 and no experiments with its variants were performed, and plaque assays to confirm viral production were not performed. As tissue donors were obese, an important area of future investigation will be to study the effects of SARS-CoV-2 infection on lean adipose tissue, as well as to study the adipose tissue of those with ‘long COVID’.

Overall, here we provide evidence that two cell types within human adipose tissue are permissive to SARS-CoV-2 infection. This adds to data showing susceptibility of other tissues including heart, kidneys, pharynx, liver, brain, and pancreas (1, 27, 107). SARS-CoV-2 RNA was detected in autopsy samples at a higher viral load than in adjacent organs, the kidney or heart. Importantly, infection of adipose tissue drives an inflammatory response in infected macrophages and preadipocytes. Thus, multiple cells within adipose tissue likely participate in both viral replication and inflammation. Importantly, we demonstrated infection and inflammation in adipose tissue adjacent to critical organs such as the heart and intestine, thus pointing to the potential for adipose tissue potentiation of organ damage in severe COVID-19. Furthermore, if adipose cells constitute a reservoir for viral infection, obesity may contribute not only to severe acute disease, but also to long-COVID syndrome. Collectively, our data implies

that infection in adipose tissue may partially explain the link between obesity and severe COVID-19. More efforts to understand the complexity and contributions of this tissue to COVID-19 pathogenesis are warranted.

MATERIALS AND METHODS

Study design: The aim of this study was to determine if human adipose tissue is permissive to SARS-CoV-2 infection. We obtained adipose tissue from consented subjects and exposed these samples to SARS-CoV-2 and measured viral entry, replication, and inflammatory pathways by flow cytometry, RTqPCR, scRNA-seq, and Luminex. All analyses were performed in an unbiased fashion. Formalin-fixed and paraffin embedded lung, kidney, adipose and heart tissue from COVID-19 autopsy samples were evaluated for viral RNA. The n value was not controlled and was dependent on availability of samples.

Subjects: Study participants were recruited from the Adult Bariatric Surgery and Cardiothoracic Surgery clinics at Stanford University Medical Center during the preoperative visit. Eligibility requirements include >25 yrs of age, and exclusion criteria included chronic inflammatory conditions, pregnancy/lactation, use of weight loss medications, and current/prior diagnosis of COVID-19. The protocol was approved by the Stanford Institutional Review Board and all subjects gave written, informed consent. Tissue samples from COVID-19 deceased patients were obtained from University Hospital Tübingen, Tübingen, Germany, or from University Hospital Basel or Cantonal Hospital Baselland, Switzerland. SARS-CoV-2 infected tissue was obtained during autopsy and processed as previously described (71). The use of SARS-CoV-2 infected tissue was approved by the ethics commission of Northern Switzerland (EKNZ; study ID: 2020-

00969). All COVID-19 patients or their relatives consented to the use of tissue for research purposes.

Preparation, isolation, and differentiation of adipose tissue: On the day of bariatric surgery, approximately 2-3g each of subcutaneous abdominal (SAT) and omental visceral adipose (VAT) tissue was harvested intraoperatively and immediately processed. For cardiothoracic surgery patients, 2g of PAT, 1g of EAT, and 1-2g of SAT chest wall was obtained intraoperatively and immediately processed. Tissue was subject to collagenase digestion for separation of mature adipocytes (MA) and SVC, and for differentiation of preadipocytes as previously described (108) with details in supplemental methods.

Virus and cell lines: The USA WA1/2020 strain of SARS-CoV-2 was obtained from BEI Resources, passaged in VeroE6 cells, and tittered by Avicel (FMC Biopolymer) overlay plaque assay on VeroE6 cells. Passage 3 virus was used for all infections. VeroE6 cells were obtained from ATCC and were mycoplasma free. A549-ACE2 was a gift from Ralf Bartenschlager and was mycoplasma free.

SARS-CoV-2 infections of differentiated adipocytes, SVC, MA, and A549-ACE2: Cells were infected with SARS-CoV-2 (2019-nCoV/USA-WA1/2020) at a MOI of 1 for 1 hour before washing input virus and replacing media for incubation. Remdesivir was used at 10 μ M.

RNA isolation and quantification: At the time of collection, cells were washed with PBS followed by incubation with TRIzol LS (Thermo) reagent for 15-20mins for cell lysis and virus

inactivation and RNA extraction. RNA was resuspended in water and quantified by absorbance (260/280) using a NanoDropTM spectrophotometer (Thermo Scientific).

Genomic and subgenomic absolute gene quantification by RTqPCR: 5µl of the total RNA was used for 1-step RTqPCR. Genomic N-gene quantification was done with the use of CDC qualified primers and probes amplifying the N1 region, n2019-nCoV (Biosearch technologies, KIT-NCOV-PP1-1000). For subgenomic *N-gene* quantification, *E-gene* sgRNA forward primer for SARS-CoV-2 leader sequence was combined with CDC N1 gene reverse primer and probe to detect N-gene sgRNA as previously shown (89, 109). RNA and primers were mixed with the TaqPath 1-step RTqPCR master mix (Applied Biosystems, A15299). A standard curve for Ct values and genome copy numbers was obtained using pET21b+ plasmid with the N-gene inserts. All the samples were analyzed in technical duplicates. The Ct cutoff for positive samples was <38 with amplification observed in both duplicates. The samples were analyzed on a StepOnePlusTM real time PCR machine (Applied Biosystems) using the following parameters: (stage 1) 10 minutes at 50°C for reverse transcription (RT), followed by (stage 2) 3 minutes at 95°C for initial denaturation and (stage 3) 40 cycles of 10 seconds at 95°C, 15 seconds at 56°C, and 5 seconds at 72°C.

RTqPCR for relative gene quantification: RNA was isolated as described above. Either the 1-step method using TaqPath (Applied Biosystems, A15299) or the 2-step process using the Superscript III first-strand synthesis system was performed (Applied biosystems, A25742) (for details see the Supplemental Materials and Material).

SARS-CoV-2 detection in autopsies: Autopsy samples were prepared as previously described (110). Briefly, RNA was isolated from formalin-fixed and paraffin embedded tissue with the use of Maxwell RSC RNA FFPE (Promega) according to manufacturer recommendations. RTqPCR was performed using the TaqMan™ 2019-nCoV control kit v1 (Thermo Scientific, A47533) to target the three viral genes: *ORF1ab*, *S*, and *N* genes, and the human *RPPH1* gene. According to the manufacturer's recommendation, a Ct value below 37 in at least two out of three viral genomic regions was considered positive. A case was considered negative if Ct values were above 40. Values between 37 and 40 were considered undetermined and the assay was repeated. Samples were always run in duplicates. RNA-ISH was used to detect SARS-CoV-2 Spike mRNA in tissue samples (for details see the Supplemental Materials and Material).

Flow cytometry: A single cell suspension was stained with Fc block, a viability stain, and surface stained for CD45, CD3, CD14, CD34, CD11c, and CD31 before fixing and permeabilizing to stain with anti-SARS-CoV-2 N protein as described in supplemental methods.

Sample preparation for Luminex: Supernatants from mock or infected SVC were collected after 24 hpi into low-binding protein collection tubes. Supernatants from mature adipocytes were collected by first removing floating mature adipocytes with a cut wide pipette tip and pipetting remaining media into low-protein binding collection tubes. Supernatants were stored at -80°C. To remove samples from BSL3 containment, supernatants were thawed and mixed with 10% TritonX-100 (Sigma-Aldrich, T9284) for a final concentration of 1% TritonX-100 and incubated for 20 minutes at room temperature for viral inactivation. Supernatants were then removed from

BSL3 and transferred to a low-binding protein 96 well plate for 80plex Luminex by the Human Immune Monitoring Center (HIMC) at Stanford University.

Single cell RNA sequencing (scRNA-seq): The gel beads-in-emulsion (GEM) single cell 3' kit v3.1 dual index kit (10X Genomics) was used following manufacturer's recommendations with slight modifications. Briefly, SVC from SAT and VAT was left untreated or infected with SARS-CoV-2 as described above. After 24hpi, cells were collected, washed, and diluted at a density of 1×10^3 cells per μl in cold DMEM (Life technologies; 11885-092) media supplemented with 10% FBS (Corning, MT35016CV). 10,000 cells per lane were loaded onto a Chromium Controller in the BSC per manufacturer's instructions. Following GEM creation, samples were transferred into PCR tube strips prior to transferring into a PTC-200 thermocycler (MJ Research) for RT. The RT parameters were the following: 45 minutes at 53°C, followed by 5 minutes at 85°C, then 15 minutes at 60°C and finally samples were kept at 4°C. Barcoded cDNA was removed to BSL2, and sequencing libraries were prepared per manufacturer's recommendation, with a TapeStation 4200 (Agilent) used for quality control. Libraries were pooled for a final concentration of 10nM and sequenced on a NovaSeq S2 (Illumina) at the Chan Zuckerberg Biohub (San Francisco).

Alignment and preprocessing of scRNA-seq data: The quality of the raw FASTQ data was examined with FASTQC and then aligned (cell ranger count) to a custom genome including human genome (hg38) and the complete genome sequence of SARS-CoV-2 (2019-nCoV/USA-WA1/2020) (GenBank: MN985325.1) using the "Cell Ranger" software package v6.0.0 (10x Genomics). R (4.0.4) was used for all downstream analyses. Resulting filtered feature-barcode-

matrices were processed using the R package Seurat (v4.0.0). Briefly, count matrices were merged and loaded into Seurat with SARS-CoV-2 counts removed and appended to the metadata. All genes represented in < 10 cells were excluded from downstream analysis. Cells were filtered based on the following criteria: less than 200 distinct genes, less than 100 unique molecular identifiers (UMIs), and greater than 15% UMIs from mitochondrial genes. Each batch was then individually normalized using the “SCTransform” function that included regression for percent mitochondria. Integration features were then calculated using the “SelectIntegrationFeatures” function and passed into “VariableFeatures” of the merged object to maintain the repeatedly variable features across each dataset. Within each batch and condition (tissue and infection status), cells identified as doublets by both “DoubletFinder” (v3) (using $pN = 0.25$, $pK = 0.09$, $PCs = 1:50$, anticipated collision rate = 10%) and scds (top 10% of cells ranked by hybrid scores) were removed ($n = 3,165$ cells) from the analysis. After applying these filtering steps, the dataset contained 198,759 high-quality cells. Principal component (PC) analysis (PCA) was performed on the data. The resulting data were corrected for batch effects using the “Harmony” package (29) with the top 50 PCs. Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) coordinate generation and clustering were performed using the “RunUMAP”, “FindNeighbors”, and “FindClusters” (resolution = 0.6) functions in Seurat with PCs 1-50. Manual annotation of each cellular cluster was performed by finding the differentially expressed genes using Seurat’s “FindAllMarkers” function with default Wilcoxon rank-sum test and comparing those markers with known cell type-specific genes from previous datasets (30, 31). “FindMarkers” function using the MAST algorithm (latent.vars = ‘participant’) based on a Bonferroni-adjusted $P < 0.05$ and a $\log_2$ fold change > 0.25 was used for targeted differential gene expression analysis.

779

780 **scRNA-seq analyses:** Gene ontology and KEGG pathway analysis was performed using R
 781 package stringdb (111). Reactome gene set enrichment analysis was performed using the R
 782 package fgsea (112), considering ranked gene lists. The Seurat function AddModuleScore() was
 783 used to score individual cells by expression of either a list of genes relating to ISGs or cytokines.
 784 This function generates an average module score by calculating the mean expression of each
 785 gene in the module corrected for expression of a random set of similarly expressing genes. Gene
 786 lists used to define each module are defined in table S15. Heatmaps were generated using
 787 ComplexHeatmap, Seurat and pheatmap packages, Violin plots were generated using ggplot2,
 788 and dotplots were generated using the Seurat packages in R. A Github repository for all original
 789 code used for analysis and visualization will be made public upon publication.

790

791 **Images:** Pictures were taken with the use of a EVOS XL core cell imaging system (Thermo
 792 Fisher Scientific) with an objective of 10x.

793

794 **Statistical analysis:** GraphPad Prism version 9.1.0 (216) and R (4.0.4) were used for statistical
 795 analysis. When comparing mock and infected groups a paired, two-sided, student's t-test was
 796 applied. When comparing more than two groups a two-way ANOVA, multiple comparisons
 797 using statistical hypothesis Sidak was performed. In Luminex analysis a paired Wilcoxon signed
 798 rank test with desired false discovery rate of 10% was performed. Data bars are always presented
 799 as $\pm$ mean s.e.m.

800

801 **Supplementary Materials**

802 Materials and Methods

803 Fig. S1. Genomic and Subgenomic measurement of SARS-CoV-2 on in vitro infected SVC.

804 Fig. S2. Validation of Remdesivir treatments in A549-ACE2 cells.

805 Fig. S3. Gating strategy of SVC in human adipose tissue.

806 Fig. S4. Limited ACE2 protein detection in SVC from SAT and VAT.

807 Fig. S5. Infection, depot and participant breakdown by cluster annotation.

808 Fig. S6. Distribution of SARS-CoV-2 transcripts across all cells.

809 Fig. S7. C2- and C12-macrophages are distinctly different upon mock and SARS-CoV-2
810 infection.

811 Fig. S8. Characterization of preadipocytes across VAT and SAT.

812 Fig. S9. Mature and *in vitro* differentiated adipocytes harbor SARS-CoV-2 RNA and mount
813 inflammatory responses after exposure to SARS-CoV-2 *in vitro*.

814 Fig. S10. Increased interferon related genes in adipose tissue post-SARS-CoV-2 infection.

815 Fig. S11. Elevated IL-6 gene expression and secretion of inflammatory mediators in SVC post in
816 vitro SARS-CoV-2 infection.

817 Table S1. Adipose tissue participant's demographic, medical information, and sample use.

818 Table S2. No expression of ACE2 in adipose tissue but increased ACE2 expression in in vitro
819 differentiated adipocytes at 3 days of differentiation.

820 Table S3. Marker genes for each cluster defined in combined Seurat analysis.

Table S4. Differentially expressed transcripts within macrophages only, across different subsets of infection, mock and depot.

Table S5. Differentially expressed transcripts between infected (SARS-CoV-2+) versus bystander populations within the C2 and C12 infected macrophage populations.

Table S6. GO and KEGG term enrichment for markers of C12 macrophages.

Table S7. GO and KEGG term enrichment for markers of C2 macrophages.

Table S8. Reactome pathways for differentially expressed genes between infected (SARS-CoV-2+) versus bystander C2 macrophages.

Table S9. Marker genes for each cluster defined from the Seurat analysis of Preadipocytes only.

Table S10. Differentially expressed genes between SARS-CoV-2 exposed versus mock exposed preadipocytes, by cluster and participant, within the SAT

Table S11. Differentially expressed genes between SARS-CoV-2 exposed versus mock exposed preadipocytes, by cluster and participant, within the VAT.

Table S12. Reactome pathways for differentially expressed genes between SARS-CoV-2 exposed versus mock exposed preadipocytes, by cluster and participant, within the SAT.

Table S13. Reactome pathways for differentially expressed genes between SARS-CoV-2 exposed versus mock exposed preadipocytes, by cluster and participant, within the VAT.

Table S14. ISG and cytokine gene modules.

References and Notes

842 1. A. Gupta, M. V. Madhavan, K. Sehgal, N. Nair, S. Mahajan, T. S. Sehrawat, B. Bikdeli, N.
843 Ahluwalia, J. C. Ausiello, E. Y. Wan, D. E. Freedberg, A. J. Kirtane, S. A. Parikh, M. S. Maurer,
844 A. S. Nordvig, D. Accili, J. M. Bathon, S. Mohan, K. A. Bauer, M. B. Leon, H. M. Krumholz, N.
845 Uriel, M. R. Mehra, M. S. V. Elkind, G. W. Stone, A. Schwartz, D. D. Ho, J. P. Bilezikian, D.
846 W. Landry, Extrapulmonary manifestations of COVID-19, *Nat Med* **26**, 1017–1032 (2020).
847 2. C. M. Petrilli, S. A. Jones, J. Yang, H. Rajagopalan, L. O'Donnell, Y. Chernyak, K. A. Tobin,
848 R. J. Cerfolio, F. Francois, L. I. Horwitz, Factors associated with hospital admission and critical
849 illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort
850 study, *Bmj* **369**, m1966 (2020).
851 3. A. Simonnet, M. Chetboun, J. Poissy, V. Raverdy, J. Noulette, A. Duhamel, J. Labreuche, D.
852 Mathieu, F. Pattou, M. Jourdain, R. Caizzo, M. Caplan, N. Cousin, T. Duburcq, A. Durand, A. E.
853 kalioubie, R. Favory, B. Garcia, P. Girardie, J. Goutay, M. Houard, E. Jaillette, N. Kostuj, G.
854 Ledoux, D. Mathieu, A. S. Moreau, C. Niles, S. Nseir, T. Onimus, E. Parmentier, S. Préau, L.
855 Robriquet, A. Rouze, S. Six, H. Verkindt, High Prevalence of *Obesity* in Severe Acute
856 Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical
857 Ventilation, *Obesity* **28**, 1195–1199 (2020).
858 4. Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to
859 COVID-19 based on an analysis of data of 150 patients from Wuhan, China, *Intens Care Med*
860 **46**, 846–848 (2020).
861 5. S. Y. Tartof, L. Qian, V. Hong, R. Wei, R. F. Nadjafi, H. Fischer, Z. Li, S. F. Shaw, S. L.
862 Caparosa, C. L. Nau, T. Saxena, G. K. Rieg, B. K. Ackerson, A. L. Sharp, J. Skarbinski, T. K.
863 Naik, S. B. Murali, Obesity and Mortality Among Patients Diagnosed With COVID-19: Results
864 From an Integrated Health Care Organization, *Ann Intern Med* **173**, 773–781 (2020).

- 865 6. B. M. Popkin, S. Du, W. D. Green, M. A. Beck, T. Algaith, C. H. Herbst, R. F. Alsukait, M.
866 Alluhidan, N. Alazemi, M. Shekar, Individuals with obesity and COVID-19: A global
867 perspective on the epidemiology and biological relationships, *Obes Rev* **21**, e13128 (2020).
- 868 7. D. Moriconi, S. Masi, E. Rebelos, A. Viridis, M. L. Manca, S. D. Marco, S. Taddei, M.
869 Nannipieri, Obesity prolongs the hospital stay in patients affected by COVID-19, and may
870 impact on SARS-COV-2 shedding, *Obes Res Clin Pract* **14**, 205–209 (2020).
- 871 8. M. Deng, Y. Qi, L. Deng, H. Wang, Y. Xu, Z. Li, Z. Meng, J. Tang, Z. Dai, Obesity as a
872 Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study,
873 *Obesity* **28**, 1815–1825 (2020).
- 874 9. C. Zammit, H. Liddicoat, I. Moonsie, H. Makker, Obesity and respiratory diseases, *Int J Gen*
875 *Medicine* **3**, 335–343 (2010).
- 876 10. G. Reaven, F. Abbasi, T. McLaughlin, Obesity, Insulin Resistance, and Cardiovascular
877 Disease, *Recent Prog Horm Res* **59**, 207–223 (2004).
- 878 11. T. McLaughlin, G. Allison, F. Abbasi, C. Lamendola, G. Reaven, Prevalence of insulin
879 resistance and associated cardiovascular disease risk factors among normal weight, overweight,
880 and obese individuals, *Metabolis* **53**, 495–499 (2004).
- 881 12. F. Abbasi, T. McLaughlin, C. Lamendola, I. Lipinska, G. Tofler, G. M. Reaven, Comparison
882 of Plasminogen Activator Inhibitor-1 Concentration in Insulin-Resistant Versus Insulin-Sensitive
883 Healthy Women, *Arterioscler Thromb Vasc Biol* **19**, 2818–21 (1999).
- 884 13. T. McLaughlin, S. E. Ackerman, L. Shen, E. Engleman, Role of innate and adaptive
885 immunity in obesity-associated metabolic disease, *J Clin Invest* **127**, 5–13 (2017).
- 886 14. H. E. Maier, R. Lopez, N. Sanchez, S. Ng, L. Gresh, S. Ojeda, R. Burger-Calderon, G. Kuan,
887 E. Harris, A. Balmaseda, A. Gordon, Obesity Increases the Duration of Influenza A Virus

888 Shedding in Adults, *J Infect Dis* **218**, 1378–1382 (2018).

889 15. M. Reiterer, M. Rajan, N. Gómez-Banoy, J. D. Lau, L. G. Gomez-Escobar, L. Ma, A. Gilani,
890 S. Alvarez-Mulett, E. T. Sholle, V. Chandar, Y. Bram, K. Hoffman, P. Bhardwaj, P. Piloco, A.
891 Rubio-Navarro, S. Uhl, L. Carrau, S. Houhgton, D. Redmond, A. P. Shukla, P. Goyal, K. A.
892 Brown, B. R. tenOever, L. C. Alonso, R. E. Schwartz, E. J. Schenck, M. M. Safford, J. C. Lo,
893 Hyperglycemia in Acute COVID-19 is Characterized by Insulin Resistance and Adipose Tissue
894 Infectivity by SARS-CoV-2, *Cell Metab* (2021), doi:10.1016/j.cmet.2021.09.009.

895 16. J. Couturier, J. W. Suliburk, J. M. Brown, D. J. Luke, N. Agarwal, X. Yu, C. Nguyen, D.
896 Iyer, C. A. Kozinetz, P. A. Overbeek, M. L. Metzker, A. Balasubramanyam, D. E. Lewis, Human
897 adipose tissue as a reservoir for memory CD4⁺ T cells and HIV, *Aids* **29**, 667–674 (2015).

898 17. H. Nishimura, S. Itamura, T. Iwasaki, T. Kurata, M. Tashiro, Characterization of human
899 influenza A (H5N1) virus infection in mice: neuro-, pneumo- and adipotropic infection, *J Gen*
900 *Virol* **81**, 2503–2510 (2000).

901 18. K. J. Zvezdaryk, M. B. Ferris, A. L. Strong, C. A. Morris, B. A. Bunnell, N. V. Dhurandhar,
902 J. M. Gimble, D. E. Sullivan, Human cytomegalovirus infection of human adipose-derived
903 stromal/stem cells restricts differentiation along the adipogenic lineage, *Adipocyte* **5**, 53–64
904 (2015).

905 19. A. Damouche, T. Lazure, V. Avettand-Fènoël, N. Huot, N. Dejucq-Rainsford, A.-P. Satie, A.
906 Mélard, L. David, C. Gomet, J. Ghosn, N. Noel, G. Pourcher, V. Martinez, S. Benoist, V.
907 Béréziat, A. Cosma, B. Favier, B. Vaslin, C. Rouzioux, J. Capeau, M. Müller-Trutwin, N.
908 Dereuddre-Bosquet, R. L. Grand, O. Lambotte, C. Bourgeois, Adipose Tissue Is a Neglected
909 Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection, *Plos Pathog*
910 **11**, e1005153 (2015).

911 20. H. Kanda, S. Tateya, Y. Tamori, K. Kotani, K. Hiasa, R. Kitazawa, S. Kitazawa, H. Miyachi,
912 S. Maeda, K. Egashira, M. Kasuga, MCP-1 contributes to macrophage infiltration into adipose
913 tissue, insulin resistance, and hepatic steatosis in obesity, *J Clin Invest* **116**, 1494–1505 (2006).
914 21. B. E. Wisse, The Inflammatory Syndrome; The Role of Adipose Tissue Cytokines in
915 Metabolic Disorders Linked to Obesity, *J Am Soc Nephrol* **15**, 2792–2800 (2004).
916 22. G. S. Hotamisligil, N. S. Shargill, B. M. Spiegelman, Adipose Expression of Tumor Necrosis
917 Factor- α : Direct Role in Obesity-Linked Insulin Resistance, *Science* **259**, 87–91 (1993).
918 23. H. Shi, M. V. Kokoeva, K. Inouye, I. Tzamelis, H. Yin, J. S. Flier, TLR4 links innate
919 immunity and fatty acid-induced insulin resistance, *J Clin Invest* **116**, 3015–3025 (2006).
920 24. T. M. Delorey, C. G. K. Ziegler, G. Heimberg, R. Normand, Y. Yang, Å. Segerstolpe, D.
921 Abbondanza, S. J. Fleming, A. Subramanian, D. T. Montoro, K. A. Jagadeesh, K. K. Dey, P.
922 Sen, M. Slyper, Y. H. Pita-Juárez, D. Phillips, J. Biermann, Z. Bloom-Ackermann, N. Barkas, A.
923 Ganna, J. Gomez, J. C. Melms, I. Katsiyv, E. Normandin, P. Naderi, Y. V. Popov, S. S. Raju, S.
924 Niezen, L. T.-Y. Tsai, K. J. Siddle, M. Sud, V. M. Tran, S. K. Vellarikkal, Y. Wang, L. Amir-
925 Zilberstein, D. S. Atri, J. Beechem, O. R. Brook, J. Chen, P. Divakar, P. Dorceus, J. M. Engreitz,
926 A. Essene, D. M. Fitzgerald, R. Fropf, S. Gazal, J. Gould, J. Grzyb, T. Harvey, J. Hecht, T.
927 Hether, J. Jané-Valbuena, M. Leney-Greene, H. Ma, C. McCabe, D. E. McLoughlin, E. M.
928 Miller, C. Muus, M. Niemi, R. Padera, L. Pan, D. Pant, C. Pe'er, J. Pfiffner-Borges, C. J. Pinto,
929 J. Plaisted, J. Reeves, M. Ross, M. Rudy, E. H. Rueckert, M. Siciliano, A. Sturm, E. Todres, A.
930 Waghray, S. Warren, S. Zhang, D. R. Zollinger, L. Cosimi, R. M. Gupta, N. Hacohen, H.
931 Hibshoosh, W. Hide, A. L. Price, J. Rajagopal, P. R. Tata, S. Riedel, G. Szabo, T. L. Tickle, P.
932 T. Ellinor, D. Hung, P. C. Sabeti, R. Novak, R. Rogers, D. E. Ingber, Z. G. Jiang, D. Juric, M.
933 Babadi, S. L. Farhi, B. Izar, J. R. Stone, I. S. Vlachos, I. H. Solomon, O. Ashenberg, C. B. M.

934 Porter, B. Li, A. K. Shalek, A.-C. Villani, O. Rozenblatt-Rosen, A. Regev, COVID-19 tissue
935 atlases reveal SARS-CoV-2 pathology and cellular targets, *Nature* **595**, 107–113 (2021).

936 25. T. T. S. Consortium, S. R. Quake, The Tabula Sapiens: a single cell transcriptomic atlas of
937 multiple organs from individual human donors, *Biorxiv*, 2021.07.19.452956 (2021).

938 26. E. Song, C. Zhang, B. Israelow, A. Lu-Culligan, A. V. Prado, S. Skriabine, P. Lu, O.-E.
939 Weizman, F. Liu, Y. Dai, K. Szigeti-Buck, Y. Yasumoto, G. Wang, C. Castaldi, J. Heltke, E. Ng,
940 J. Wheeler, M. M. Alfajaro, E. Levavasseur, B. Fontes, N. G. Ravindra, D. V. Dijk, S. Mane, M.
941 Gunel, A. Ring, S. A. J. Kazmi, K. Zhang, C. B. Wilen, T. L. Horvath, I. Plu, S. Haik, J.-L.
942 Thomas, A. Louvi, S. F. Farhadian, A. Huttner, D. Seilhean, N. Renier, K. Bilguvar, A. Iwasaki,
943 Neuroinvasion of SARS-CoV-2 in human and mouse brain, *J Exp Med* **218**, e20202135 (2021).

944 27. J. A. Müller, R. Groß, C. Conzelmann, J. Krüger, U. Merle, J. Steinhart, T. Weil, L. Koepke,
945 C. P. Bozzo, C. Read, G. Fois, T. Eiseler, J. Gehrmann, J. van Vuuren, I. M. Wessbecher, M.
946 Frick, I. G. Costa, M. Breunig, B. Grüner, L. Peters, M. Schuster, S. Liebau, T. Seufferlein, S.
947 Stenger, A. Stenzinger, P. E. MacDonald, F. Kirchhoff, K. M. J. Sparrer, P. Walther, H. Lickert,
948 T. F. E. Barth, M. Wagner, J. Münch, S. Heller, A. Kleger, SARS-CoV-2 infects and replicates
949 in cells of the human endocrine and exocrine pancreas, *Nat Metabolism* **3**, 149–165 (2021).

950 28. M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. S.
951 Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M. A. Müller, C. Drosten, S. Pöhlmann, SARS-
952 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
953 Protease Inhibitor, *Cell* **181**, 271-280.e8 (2020).

954 29. I. Korsunsky, N. Millard, J. Fan, K. Slowikowski, F. Zhang, K. Wei, Y. Baglaenko, M.
955 Brenner, P. Loh, S. Raychaudhuri, Fast, sensitive and accurate integration of single-cell data
956 with Harmony, *Nat Methods* **16**, 1289–1296 (2019).

30. J. Vijay, M.-F. Gauthier, R. L. Biswell, D. A. Louiselle, J. J. Johnston, W. A. Cheung, B. Belden, A. Pramatarova, L. Biertho, M. Gibson, M.-M. Simon, H. Djambazian, A. Staffa, G. Bourque, A. Laitinen, J. Nystedt, M.-C. Vohl, J. D. Fraser, T. Pastinen, A. Tchernof, E. Grundberg, Single-cell analysis of human adipose tissue identifies depot- and disease-specific cell types, *Nat Metabolism* 2, 97–109 (2020).
31. A. D. Hildreth, F. Ma, Y. Y. Wong, R. Sun, M. Pellegrini, T. E. O’Sullivan, Single-cell sequencing of human white adipose tissue identifies new cell states in health and obesity, *Nat Immunol* , 1–15 (2021).
32. Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y. Yuen, Q. Wang, H. Zhou, J. Yan, J. Qi, Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2, *Cell* 181, 894-904.e9 (2020).
33. M.-M. Zhao, W.-L. Yang, F.-Y. Yang, L. Zhang, W.-J. Huang, W. Hou, C.-F. Fan, R.-H. Jin, Y.-M. Feng, Y.-C. Wang, J.-K. Yang, Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development, *Signal Transduct Target Ther* 6, 134 (2021).
34. L. Cantuti-Castelvetri, R. Ojha, L. D. Pedro, M. Djannatian, J. Franz, S. Kuivanen, F. van der Meer, K. Kallio, T. Kaya, M. Anastasina, T. Smura, L. Levanov, L. Szirovicza, A. Tobi, H. Kallio-Kokko, P. Österlund, M. Joensuu, F. A. Meunier, S. J. Butcher, M. S. Winkler, B. Mollenhauer, A. Helenius, O. Gokce, T. Teesalu, J. Hepojoki, O. Vapalahti, C. Stadelmann, G. B. and M. Simons, Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity, (2020).
35. J. Huber, F. W. Kiefer, M. Zeyda, B. Ludvik, G. R. Silberhumer, G. Prager, G. J. Zlabinger, T. M. Stulnig, CC Chemokine and CC Chemokine Receptor Profiles in Visceral and Subcutaneous Adipose Tissue Are Altered in Human Obesity, *J Clin Endocrinol Metabolism* 93,

980 3215–3221 (2008).

981 36. K. Asano, N. Takahashi, M. Ushiki, M. Monya, F. Aihara, E. Kuboki, S. Moriyama, M. Iida,
982 H. Kitamura, C.-H. Qiu, T. Watanabe, M. Tanaka, Intestinal CD169⁺ macrophages initiate
983 mucosal inflammation by secreting CCL8 that recruits inflammatory monocytes, *Nat Commun* **6**,
984 7802 (2015).

985 37. S. Chakarov, H. Y. Lim, L. Tan, S. Y. Lim, P. See, J. Lum, X.-M. Zhang, S. Foo, S.
986 Nakamizo, K. Duan, W. T. Kong, R. Gentek, A. Balachander, D. Carbajo, C. Bleriot, B.
987 Malleret, J. K. C. Tam, S. Baig, M. Shabeer, S.-A. E. S. Toh, A. Schlitzer, A. Larbi, T. Marichal,
988 B. Malissen, J. Chen, M. Poidinger, K. Kabashima, M. Bajenoff, L. G. Ng, V. Angeli, F.
989 Ginhoux, Two distinct interstitial macrophage populations coexist across tissues in specific
990 subtissular niches, *Science* **363**, eaau0964 (2019).

991 38. W.-K. Kim, X. Alvarez, J. Fisher, B. Bronfin, S. Westmoreland, J. McLaurin, K. Williams,
992 CD163 Identifies Perivascular Macrophages in Normal and Viral Encephalitic Brains and
993 Potential Precursors to Perivascular Macrophages in Blood, *Am J Pathology* **168**, 822–834
994 (2006).

995 39. M. Kratz, B. R. Coats, K. B. Hisert, D. Hagman, V. Mutskov, E. Peris, K. Q. Schoenfelt, J.
996 N. Kuzma, I. Larson, P. S. Billing, R. W. Landerholm, M. Crouthamel, D. Gozal, S. Hwang, P.
997 K. Singh, L. Becker, Metabolic Dysfunction Drives a Mechanistically Distinct Proinflammatory
998 Phenotype in Adipose Tissue Macrophages, *Cell Metab* **20**, 614–625 (2014).

999 40. L. Lu, H. Zhang, D. J. Dauphars, and Y.-W. He, A Potential Role of Interleukin 10 in
1000 COVID-19 Pathogenesis, (2021).

1001 41. E. Mick, J. Kamm, A. O. Pisco, K. Ratnasiri, J. M. Babik, G. Castañeda, J. L. DeRisi, A. M.
1002 Detweiler, S. L. Hao, K. N. Kangelaris, G. R. Kumar, L. M. Li, S. A. Mann, N. Neff, P. A.

1003 Prasad, P. H. Serpa, S. J. Shah, N. Spottiswoode, M. Tan, C. S. Calfee, S. A. Christenson, A.
 1004 Kistler, C. Langelier, Upper airway gene expression reveals suppressed immune responses to
 1005 SARS-CoV-2 compared with other respiratory viruses, *Nat Commun* **11**, 5854 (2020).
 1006 42. D. Bojkova, K. Klann, B. Koch, M. Widera, D. Krause, S. Ciesek, J. Cinatl, C. Münch,
 1007 Proteomics of SARS-CoV-2-infected host cells reveals therapy targets, *Nature* **583**, 469–472
 1008 (2020).
 1009 43. W. Kamitani, C. Huang, K. Narayanan, K. G. Lokugamage, S. Makino, A two-pronged
 1010 strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein, *Nat Struct Mol*
 1011 *Biol* **16**, 1134–1140 (2009).
 1012 44. B. Gustafson, S. Gogg, S. Hedjazifar, L. Jenndahl, A. Hammarstedt, U. Smith, Inflammation
 1013 and impaired adipogenesis in hypertrophic obesity in man, *Am J Physiol-endoc M* **297**, E999–
 1014 E1003 (2009).
 1015 45. C. Hepler, B. Shan, Q. Zhang, G. H. Henry, M. Shao, L. Vishvanath, A. L. Ghaben, A. B.
 1016 Mobley, D. Strand, G. C. Hon, R. K. Gupta, Identification of functionally distinct fibro-
 1017 inflammatory and adipogenic stromal subpopulations in visceral adipose tissue of adult mice,
 1018 *Elife* **7**, e39636 (2018).
 1019 46. Y.-Y. Chau, R. Bandiera, A. Serrels, O. M. Martínez-Estrada, W. Qing, M. Lee, J. Slight, A.
 1020 Thornburn, R. Berry, S. McHaffie, R. H. Stimson, B. R. Walker, R. M. Chapuli, A. Schedl, N.
 1021 Hastie, Visceral and subcutaneous fat have different origins and evidence supports a mesothelial
 1022 source, *Nat Cell Biol* **16**, 367–375 (2014).
 1023 47. A. J. Wilk, M. J. Lee, B. Wei, B. Parks, R. Pi, G. J. Martínez-Colón, T. Ranganath, N. Q.
 1024 Zhao, S. Taylor, W. Becker, S. C.-19 Biobank, T. Ranganath, N. Q. Zhao, A. J. Wilk, R.
 1025 Vergara, J. L. McKechnie, L. de la Parte, K. W. Dantzler, M. Ty, N. Kathale, G. J. Martinez-

1026 Colon, A. Rustagi, G. Ivison, R. Pi, M. J. Lee, R. Brewer, T. Hollis, A. Baird, M. Ugur, M. Tal,
1027 D. Bogusch, G. Nahass, K. Haider, K. Q. T. Tran, L. Simpson, H. Din, J. Roque, R. Mann, I.
1028 Chang, E. Do, A. Fernandes, S.-C. Lyu, W. Zhang, M. Manohar, J. Krempski, A. Visweswaran,
1029 E. J. Zudock, K. Jee, K. Kumar, J. A. Newberry, J. V. Quinn, D. Schreiber, E. A. Ashley, C. A.
1030 Blish, A. L. Blomkalns, K. C. Nadeau, R. O'Hara, A. J. Rogers, S. Yang, D. Jimenez-Morales,
1031 A. L. Blomkalns, R. O'Hara, E. A. Ashley, K. C. Nadeau, S. Yang, S. Holmes, M. Rabinovitch,
1032 A. J. Rogers, W. J. Greenleaf, C. A. Blish, Multi-omic profiling reveals widespread
1033 dysregulation of innate immunity and hematopoiesis in COVID-19, *J Exp Med* 218, e20210582
1034 (2021).

1035 48. E. Papalexi, E. P. Mimitou, A. W. Butler, S. Foster, B. Bracken, W. M. Mauck, H.-H.
1036 Wessels, Y. Hao, B. Z. Yeung, P. Smibert, R. Satija, Characterizing the molecular regulation of
1037 inhibitory immune checkpoints with multimodal single-cell screens, *Nat Genet* **53**, 322–331
1038 (2021).

1039 49. Y. Chen, J. Wang, C. Liu, L. Su, D. Zhang, J. Fan, Y. Yang, M. Xiao, J. Xie, Y. Xu, Y. Li, S.
1040 Zhang, IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19, *Mol Med*
1041 **26**, 97 (2020).

1042 50. Y. Yang, C. Shen, J. Li, J. Yuan, J. Wei, F. Huang, F. Wang, G. Li, Y. Li, L. Xing, L. Peng,
1043 M. Yang, M. Cao, H. Zheng, W. Wu, R. Zou, D. Li, Z. Xu, H. Wang, M. Zhang, Z. Zhang, G. F.
1044 Gao, C. Jiang, L. Liu, Y. Liu, Plasma IP-10 and MCP-3 levels are highly associated with disease
1045 severity and predict the progression of COVID-19, *J Allergy Clin Immun* **146**, 119-127.e4
1046 (2020).

1047 51. A. C. Petrey, F. Qeadan, E. A. Middleton, I. V. Pinchuk, R. A. Campbell, E. J. Beswick,
1048 Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic

1049 factors differ in severity of disease and sex, *J Leukocyte Biol* **109**, 55–66 (2021).

1050 52. L. Zhou, K. Huntington, S. Zhang, L. Carlsen, E.-Y. So, C. Parker, I. Sahin, H. Safran, S.

1051 Kamle, C.-M. Lee, C. G. Lee, J. A. Elias, K. S. Campbell, M. T. Naik, W. J. Atwood, E.

1052 Youssef, J. A. Pachter, A. Navaraj, A. A. Seyhan, O. Liang, W. S. El-Deiry, Natural Killer cell

1053 activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S

1054 pseudovirus infectivity by MEK inhibitor treatment of human cells, *Biorxiv* , 2020.08.02.230839

1055 (2020).

1056 53. M. Blot, M. Jacquier, L.-S. A. Glele, G. Beltramo, M. Nguyen, P. Bonniaud, S. Prin, P.

1057 Andreu, B. Bouhemad, J.-B. Bour, C. Biquet, L. Piroth, J.-P. P. de Barros, D. Masson, J.-P.

1058 Quenot, P.-E. Charles, P. study group, F. Aptel, A. Dargent, M. Georges, M. Labruyère, L.

1059 Lagrost, A. Large, S. Monier, J.-B. Roudaut, C. Thomas, CXCL10 could drive longer duration of

1060 mechanical ventilation during COVID-19 ARDS, *Crit Care* **24**, 632 (2020).

1061 54. M. Blot, J.-B. Bour, J. P. Quenot, A. Bourredjem, M. Nguyen, J. Guy, S. Monier, M.

1062 Georges, A. Large, A. Dargent, A. Guilhem, S. Mouries-Martin, J. Barben, B. Bouhemad, P.-E.

1063 Charles, P. Chavanet, C. Biquet, L. Piroth, P. Andreu, F. Aptel, M. Labruyère, S. Prin, G.

1064 Beltramo, P. Bonniaud, P. Bielefeld, H. Devilliers, B. Bonnotte, M. Buisson, A. Putot, The

1065 dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer

1066 outcome, *J Transl Med* **18**, 457 (2020).

1067 55. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z.

1068 Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo,

1069 J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected

1070 with 2019 novel coronavirus in Wuhan, China, *Lancet* **395**, 497–506 (2020).

1071 56. J. T. Sims, V. Krishnan, C.-Y. Chang, S. M. Engle, G. Casalini, G. H. Rodgers, N. Bivi, B. J.

1072 Nickoloff, R. J. Konrad, S. de Bono, R. E. Higgs, R. J. Benschop, S. Ottaviani, A. Cardoso, A.
1073 Nirula, M. Corbellino, J. Stebbing, Characterization of the cytokine storm reflects
1074 hyperinflammatory endothelial dysfunction in COVID-19, *J Allergy Clin Immun* **147**, 107–111
1075 (2021).

1076 57. C. R. Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D. Weiskopf, S.
1077 Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A. Rawlings, J.
1078 Mateus, L. P. V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E. O. Saphire, D. M. Smith,
1079 A. Sette, S. Crotty, Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19
1080 and Associations with Age and Disease Severity, *Cell* **183**, 996-1012.e19 (2020).

1081 58. A. M. Horspool, T. Kieffer, B. P. Russ, M. A. DeJong, M. A. Wolf, J. M. Karakiozis, B. J.
1082 Hickey, P. Fagone, D. H. Tacker, J. R. Bever, I. Martinez, M. Barbier, P. L. Perrotta, F. H.
1083 Damron, Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel
1084 Biomarker of Lethal SARS-CoV-2 Infection, *Msphere* **6** (2021), doi:10.1128/msphere.01324-20.

1085 59. C.-M. Su, L. Wang, D. Yoo, Activation of NF- κ B and induction of proinflammatory cytokine
1086 expressions mediated by ORF7a protein of SARS-CoV-2, *Sci Rep-uk* **11**, 13464 (2021).

1087 60. X.-X. Yin, X.-R. Zheng, W. Peng, M.-L. Wu, X.-Y. Mao, Vascular Endothelial Growth
1088 Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak, *Acs*
1089 *Chem Neurosci* **11**, 1704–1705 (2020).

1090 61. S. M. Metcalfe, LIF and the lung's stem cell niche: is failure to use LIF to protect against
1091 COVID-19 a grave omission in managing the pandemic?, *Future Virol* **15**, 659–662 (2020).

1092 62. C. Bleilevens, J. Soppert, A. Hoffmann, T. Breuer, J. Bernhagen, L. Martin, L. Stiehler, G.
1093 Marx, M. Dreher, C. Stoppe, T.-P. Simon, Macrophage Migration Inhibitory Factor (MIF)
1094 Plasma Concentration in Critically Ill COVID-19 Patients: A Prospective Observational Study,

1095 *Diagnostics* **11**, 332 (2021).

1096 63. N. A. A. Öztürk, A. Ursavaş, A. G. Dilektaşlı, E. Demirdöğen, N. F. Coşkun, D. Ediger, A.

1097 E. Uzaslan, D. Y. Ermiş, M. Karaca, O. E. Terzi, M. Bayram, D. Ö. Topçu, B. Yiğitliler, A.

1098 Yurttaş, S. Maharramov, G. Yazici, H. B. Oral, M. Karadağ, Interleukin-21: A Potential

1099 Biomarker For Diagnosis and Predicting Prognosis in COVID-19 Patients, *Turk J Med Sci*

1100 (2021), doi:10.3906/sag-2102-24.

1101 64. A. G. Vassiliou, C. Keskinidou, E. Jahaj, P. Gallos, I. Dimopoulou, A. Kotanidou, S. E.

1102 Orfanos, ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in

1103 Critically Ill COVID-19 Patients, *Cells* **10**, 186 (2021).

1104 65. P. Sabaka, A. Koščálová, I. Straka, J. Hodosy, R. Lipták, B. Kmotorková, M. Kachlíková, A.

1105 Kušnírová, Role of interleukin 6 as a predictive factor for a severe course of Covid-19:

1106 retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak,

1107 *Bmc Infect Dis* **21**, 308 (2021).

1108 66. K. Timper, J. L. Denson, S. M. Steculorum, C. Heilinger, L. Engström-Ruud, C. M.

1109 Wunderlich, S. Rose-John, F. T. Wunderlich, J. C. Brüning, IL-6 Improves Energy and Glucose

1110 Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling, *Cell Reports* **19**, 267–280

1111 (2017).

1112 67. S. A. Jones, C. A. Hunter, Is IL-6 a key cytokine target for therapy in COVID-19?, *Nat Rev*

1113 *Immunol* **21**, 337–339 (2021).

1114 68. N. A. Baker, L. A. Muir, C. N. Lumeng, R. W. O'Rourke, Thermogenic Fat, Methods and

1115 Protocols, *Methods Mol Biology* **1566**, 61–76 (2017).

1116 69. T. Garin-Shkolnik, A. Rudich, G. S. Hotamisligil, M. Rubinstein, FABP4 Attenuates PPAR

1117 and Adipogenesis and Is Inversely Correlated With PPAR in Adipose Tissues, *Diabetes* **63**,

1118 900–911 (2013).

1119 70. R. Nienhold, Y. Ciani, V. H. Koelzer, A. Tzankov, J. D. Haslbauer, T. Menter, N. Schwab,
1120 M. Henkel, A. Frank, V. Zsikla, N. Willi, W. Kempf, T. Hoyler, M. Barbareschi, H. Moch, M.
1121 Tolnay, G. Cathomas, F. Demichelis, T. Junt, K. D. Mertz, Two distinct immunopathological
1122 profiles in autopsy lungs of COVID-19, *Nat Commun* **11**, 5086 (2020).

1123 71. T. Menter, J. D. Haslbauer, R. Nienhold, S. Savic, H. Hopfer, N. Deigendesch, S. Frank, D.
1124 Turek, N. Willi, H. Pargger, S. Bassetti, J. D. Leuppi, G. Cathomas, M. Tolnay, K. D. Mertz, A.
1125 Tzankov, Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with
1126 severe capillary congestion and variegated findings in lungs and other organs suggesting vascular
1127 dysfunction, *Histopathology* **77**, 198–209 (2020).

1128 72. J. D. Haslbauer, A. Tzankov, K. D. Mertz, N. Schwab, R. Nienhold, R. Twerenbold, G.
1129 Leibundgut, A. K. Stalder, M. Matter, K. Glatz, Characterisation of cardiac pathology in 23
1130 autopsies of lethal COVID-19, *J Pathology Clin Res* **7**, 326–337 (2021).

1131 73. D. L. Morris, K. Singer, and C. N. Lumenga, Adipose tissue macrophages: phenotypic
1132 plasticity and diversity in lean and obese states, (2011).

1133 74. A. Lapenna, M. D. Palma, C. E. Lewis, Perivascular macrophages in health and disease, *Nat*
1134 *Rev Immunol* **18**, 689–702 (2018).

1135 75. H. Koppensteiner, R. Brack-Werner, M. Schindler, Macrophages and their relevance in
1136 Human Immunodeficiency Virus Type I infection, *Retrovirology* **9**, 82 (2012).

1137 76. J. K. Mann, T. Ndung'u, The potential of lactoferrin, ovotransferrin and lysozyme as
1138 antiviral and immune-modulating agents in COVID-19, *Future Virol* **15**, 609–624 (2020).

1139 77. S. Lee-Huang, V. Maiorov, P. L. Huang, A. Ng, H. C. Lee, Y.-T. Chang, N. Kallenbach, P.
1140 L. Huang, H.-C. Chen, Structural and Functional Modeling of Human Lysozyme Reveals a

1141 Unique Nonapeptide, HL9, with Anti-HIV Activity †, *Biochemistry-us* **44**, 4648–4655 (2005).

1142 78. J. Małaczewska, E. Kaczorek-Łukowska, R. Wójcik, A. K. Siwicki, Antiviral effects of nisin,
1143 lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus, *Bmc Vet Res* **15**,
1144 318 (2019).

1145 79. G. PANG, R. CLANCY, M. CONG, M. ORTEGA, R. ZHIGANG, G. REEVES, Influenza
1146 Virus Inhibits Lysozyme Secretion by Sputum Neutrophils in Subjects with Chronic Bronchial
1147 Sepsis, **161**, 718–722 (2000).

1148 80. P. S. Arunachalam, F. Wimmers, C. K. P. Mok, R. A. P. M. Perera, M. Scott, T. Hagan, N.
1149 Sigal, Y. Feng, L. Bristow, O. T.-Y. Tsang, D. Wagh, J. Coller, K. L. Pellegrini, D. Kazmin, G.
1150 Alaaeddine, W. S. Leung, J. M. C. Chan, T. S. H. Chik, C. Y. C. Choi, C. Huerta, M. P.
1151 McCullough, H. Lv, E. Anderson, S. Edupuganti, A. A. Upadhyay, S. E. Bosinger, H. T.
1152 Maecker, P. Khatri, N. Roupael, M. Peiris, B. Pulendran, Systems biological assessment of
1153 immunity to mild versus severe COVID-19 infection in humans, *Science* **369**, 1210–1220
1154 (2020).

1155 81. A. J. Wilk, A. Rustagi, N. Q. Zhao, J. Roque, G. J. Martínez-Colón, J. L. McKechnie, G. T.
1156 Ivison, T. Ranganath, R. Vergara, T. Hollis, L. J. Simpson, P. Grant, A. Subramanian, A. J.
1157 Rogers, C. A. Blish, A single-cell atlas of the peripheral immune response in patients with severe
1158 COVID-19, *Nat Med* **26**, 1070–1076 (2020).

1159 82. J. Tynell, V. Westenius, E. Rönkkö, V. J. Munster, K. Melén, P. Österlund, I. Julkunen,
1160 Middle East respiratory syndrome coronavirus shows poor replication but significant induction
1161 of antiviral responses in human monocyte-derived macrophages and dendritic cells, *J Gen Virol*
1162 **97**, 344–355 (2016).

1163 83. J. Zhou, H. Chu, C. Li, B. H.-Y. Wong, Z.-S. Cheng, V. K.-M. Poon, T. Sun, C. C.-Y. Lau,

1164 K. K.-Y. Wong, J. Y.-W. Chan, J. F.-W. Chan, K. K.-W. To, K.-H. Chan, B.-J. Zheng, K.-Y.
1165 Yuen, Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant
1166 Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for
1167 Pathogenesis, *J Infect Dis* 209, 1331–1342 (2014).

1168 84. C. Y. Cheung, L. L. M. Poon, I. H. Y. Ng, W. Luk, S.-F. Sia, M. H. S. Wu, K.-H. Chan, K.-
1169 Y. Yuen, S. Gordon, Y. Guan, J. S. M. Peiris, Cytokine Responses in Severe Acute Respiratory
1170 Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis, *J*
1171 *Virol* **79**, 7819–7826 (2005).

1172 85. K. P. Y. Hui, M.-C. Cheung, R. A. P. M. Perera, K.-C. Ng, C. H. T. Bui, J. C. W. Ho, M. M.
1173 T. Ng, D. I. T. Kuok, K. C. Shih, S.-W. Tsao, L. L. M. Poon, M. Peiris, J. M. Nicholls, M. C. W.
1174 Chan, Tropism, replication competence, and innate immune responses of the coronavirus SARS-
1175 CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures,
1176 *Lancet Respir Medicine* **8**, 687–695 (2020).

1177 86. X. Cao, Y. Tian, V. Nguyen, Y. Zhang, C. Gao, R. Yin, W. Carver, D. Fan, H. Albrecht, T.
1178 Cui, W. Tan, Spike Protein of SARS-CoV-2 Activates Macrophages and Contributes to
1179 Induction of Acute Lung Inflammations in Mice, *Biorxiv* , 2020.12.07.414706 (2020).

1180 87. R. A. Grant, L. Morales-Nebreda, N. S. Markov, S. Swaminathan, M. Querrey, E. R.
1181 Guzman, D. A. Abbott, H. K. Donnelly, A. Donayre, I. A. Goldberg, Z. M. Klug, N. Borkowski,
1182 Z. Lu, H. Kihshen, Y. Politanska, L. Sichizya, M. Kang, A. Shilatifard, C. Qi, J. W. Lomasney,
1183 A. C. Argento, J. M. Kruser, E. S. Malsin, C. O. Pickens, S. B. Smith, J. M. Walter, A. E.
1184 Pawlowski, D. Schneider, P. Nannapaneni, H. Abdala-Valencia, A. Bharat, C. J. Gottardi, G. R.
1185 S. Budinger, A. V. Misharin, B. D. Singer, R. G. Wunderink, R. A. Grant, L. Morales-Nebreda,
1186 N. S. Markov, S. Swaminathan, M. Querrey, E. R. Guzman, D. A. Abbott, H. K. Donnelly, A.

1187 Donayre, I. A. Goldberg, Z. M. Klug, N. Borkowski, Z. Lu, H. Kihshen, Y. Politanska, L.

1188 Sichizya, M. Kang, A. Shilatifard, C. Qi, J. W. Lomasney, A. C. Argento, J. M. Kruser, E. S.

1189 Malsin, C. O. Pickens, S. B. Smith, J. M. Walter, A. E. Pawlowski, D. Schneider, P.

1190 Nannapaneni, H. Abdala-Valencia, A. Bharat, C. J. Gottardi, G. R. S. Budinger, A. V. Misharin,

1191 B. D. Singer, R. G. Wunderink, A. A. Wagh, A. R. Hauser, A. R. Wolfe, A. Thakrar, A. V.

1192 Yeldandi, A. A. Wang, A. R. Levenson, A. M. Joudi, B. Tran, C. A. Gao, C. Kurihara, C. J.

1193 Schroedl, C. M. Horvath, D. Meza, D. D. Odell, D. W. Kamp, D. R. Winter, E. A. Ozer, E. D.

1194 Shanes, E. T. Bartom, E. J. Rendleman, E. M. Leibenguth, F. Wehbe, G. Y. Liu, G. T. Gadhvi,

1195 H. T. Navarro, J. I. Sznajder, J. E. Dematte, J. Le, J. M. Arnold, J. C. Du, J. Coleman, J. I.

1196 Bailey, J. S. Deters, J. A. Fiala, J. Starren, K. M. Ridge, K. Secunda, K. Aren, K. L. Gates, K.

1197 Todd, L. D. Gradone, L. N. Textor, L. F. Wolfe, L. L. Pesce, L. A. N. Amaral, M. L.

1198 Rosenbaum, M. Kandpal, M. Jain, M. A. Sala, M. Saine, M. Carns, M. J. Alexander, M. J.

1199 Cuttica, M. H. Prickett, N. H. Khan, N. S. Chandel, N. D. Soulaakis, O. R. Rivas, P. C. Seed, P.

1200 A. Reyfman, P. D. Go, P. H. S. Sporn, P. R. Cooper, R. Tomic, R. Patel, R. Garza-Castillon, R.

1201 Kalhan, R. I. Morimoto, R. J. Mylvaganam, S. S. Kim, S. W. M. Gatesy, S. Thakkar, S. B.

1202 Maamar, S. Han, S. R. Rosenberg, S. Nozick, S. J. Green, S. R. Russell, T. A. Poor, T. J. Zak, T.

1203 A. Lombardo, T. Stoeger, T. Shamaly, Z. Ren, Circuits between infected macrophages and T

1204 cells in SARS-CoV-2 pneumonia, *Nature* **590**, 635–641 (2021).

1205 88. D. Kim, J.-Y. Lee, J.-S. Yang, J. W. Kim, V. N. Kim, H. Chang, The Architecture of SARS-

1206 CoV-2 Transcriptome, *Cell* **181**, 914-921.e10 (2020).

1207 89. R. Verma, E. Kim, G. J. Martinez-Colón, P. Jagannathan, A. Rustagi, J. Parsonnet, H.

1208 Bonilla, C. Khosla, M. Holubar, A. Subramanian, U. Singh, Y. Maldonado, C. A. Blish, J. R.

1209 Andrews, SARS-CoV-2 subgenomic RNA kinetics in longitudinal clinical samples, *Open Forum*

1210 *Infect Dis* **8**, ofab310- (2021).

1211 90. D. E. Dimcheff, A. L. Valesano, K. E. Rumfelt, W. J. Fitzsimmons, C. Blair, C. Mirabelli, J.

1212 G. Petrie, E. T. Martin, C. Bhambhani, M. Tewari, A. S. Luring, SARS-CoV-2 Total and

1213 Subgenomic RNA Viral Load in Hospitalized Patients, *J Infect Dis* , jiab215- (2021).

1214 91. M. Bushell, P. Sarnow, Hijacking the translation apparatus by RNA viruses, *J Cell Biology*

1215 **158**, 395–399 (2002).

1216 92. B. Gustafson, U. Smith, Cytokines Promote Wnt Signaling and Inflammation and Impair the

1217 Normal Differentiation and Lipid Accumulation in 3T3-L1 Preadipocytes*, *J Biol Chem* **281**,

1218 9507–9516 (2006).

1219 93. M. Watanabe, D. Caruso, D. Tuccinardi, R. Risi, M. Zerunian, M. Polici, F. Pucciarelli, M.

1220 Tarallo, L. Strigari, S. Manfrini, S. Mariani, S. Basciani, C. Lubrano, A. Laghi, L. Gnessi,

1221 Visceral fat shows the strongest association with the need of intensive care in patients with

1222 COVID-19, *Metabolis* **111**, 154319 (2020).

1223 94. H. Chandarana, B. Dane, A. Mikheev, M. T. Taffel, Y. Feng, H. Rusinek, Visceral adipose

1224 tissue in patients with COVID-19: risk stratification for severity, *Abdom Radiol* **46**, 818–825

1225 (2021).

1226 95. S. Battisti, C. Pedone, N. Napoli, E. Russo, V. Agnoletti, S. G. Nigra, C. Dengo, M.

1227 Mughetti, C. Conte, P. Pozzilli, E. Giampalma, R. Strollo, Computed Tomography Highlights

1228 Increased Visceral Adiposity Associated With Critical Illness in COVID-19, *Diabetes Care* **43**,

1229 e129–e130 (2020).

1230 96. S. M. Reilly, A. R. Saltiel, Adapting to obesity with adipose tissue inflammation, *Nat Rev*

1231 *Endocrinol* **13**, 633–643 (2017).

1232 97. B. Glatthaar-Saalmüller, K. H. Mair, A. Saalmüller, Antiviral activity of aspirin against RNA

- 1233 viruses of the respiratory tract—an in vitro study, *Influenza Other Resp* **11**, 85–92 (2017).
- 1234 98. A. B. Goldfine, V. Fonseca, K. A. Jablonski, Y.-D. I. Chen, L. Tipton, M. A. Staten, S. E.
- 1235 Shoelson, T. I. U. S. in T. 2 D. S. Team, Salicylate (Salsalate) in Patients With Type 2 Diabetes:
- 1236 A Randomized Trial, *Ann Intern Med* **159**, 1 (2013).
- 1237 99. V. Bianconi, F. Violi, F. Fallarino, P. Pignatelli, A. Sahebkar, M. Pirro, Is Acetylsalicylic
- 1238 Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?, *Drugs* **80**, 1383–
- 1239 1396 (2020).
- 1240 100. S. E, Y. ZX, F. VJ, H. ES, E. SE., Aspirin attenuates cytomegalovirus infectivity and gene
- 1241 expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells., *Circ Res*.
- 1242 (1998), doi:10.1161/01.res.83.2.210.
- 1243 101. A. Sánchez-García, C. P. Ríos-Ibarra, A. R. Rincón-Sánchez, R. Ortiz-López, A. Garza-
- 1244 Juárez, J. Morlett-Chávez, H. Martínez-Rodríguez, A. M. Rivas-Estilla, Use of proteomic
- 1245 analysis tools to identify HCV-proteins down-regulated by acetylsalicylic acid, *Ann Hepatol* **12**,
- 1246 725–732 (2013).
- 1247 102. C. Müller, M. Hardt, D. Schwudke, B. W. Neuman, S. Pleschka, J. Ziebuhr, Inhibition of
- 1248 Cytosolic Phospholipase A2 α Impairs an Early Step of Coronavirus Replication in Cell Culture,
- 1249 *J Virol* **92**, e01463-17 (2018).
- 1250 103. P. V, B. S, D. B. G, B. M, In vitro activity of acetylsalicylic acid on replication of varicella-
- 1251 zoster virus, *New Microbiol.* (n.d.).
- 1252 104. S. F. Masre, N. F. Jufri, F. W. Ibrahim, S. H. A. Raub, Classical and alternative receptors
- 1253 for SARS-CoV-2 therapeutic strategy, *Rev Med Virol* **31**, 1–9 (2021).
- 1254 105. M. Puray-Chavez, K. M. LaPak, T. P. Schrank, J. L. Elliott, D. P. Bhatt, M. J. Agajanian, R.
- 1255 Jasuja, D. Q. Lawson, K. Davis, P. W. Rothlauf, Z. Liu, H. Jo, N. Lee, K. Tenneti, J. E.

1256 Eschbach, C. S. Mugisha, E. M. Cousins, E. W. Cloer, H. R. Vuong, L. A. VanBlargan, A. L.
1257 Bailey, P. Gilchuk, J. E. Crowe, M. S. Diamond, D. N. Hayes, S. P. J. Whelan, A. Horani, S. L.
1258 Brody, D. Goldfarb, M. B. Major, S. B. Kutluay, Systematic analysis of SARS-CoV-2 infection
1259 of an ACE2-negative human airway cell, *Cell Reports* 36, 109364 (2021).
1260 106. J. Davies, H. S. Randeva, K. Chatha, M. Hall, D. A. Spandidos, E. Karteris, I. Kyrou,
1261 Neuropilin-1 as a new potential SARS-CoV-2 infection mediator implicated in the neurologic
1262 features and central nervous system involvement of COVID-19, *Mol Med Rep* **22**, 4221–4226
1263 (2020).
1264 107. P. VG, L. M, L. MT, S. JP, W. MN, A. L, C. S, H. A, W. N, L. S, B. F, L. S, P. S, S. AS, E.
1265 C, G. O, G. M, W. D, W. T, K. S, P. K, A. M, H. TB., Multiorgan and Renal Tropism of SARS-
1266 CoV-2, *N Engl J Med* (2020), doi:10.1056/nejmc2011400.
1267 108. L. J. Liew, H. T. Ong, R. J. Dilley, Isolation and Culture of Adipose-Derived Stromal Cells
1268 from Subcutaneous Fat, *Methods Mol Biology* **1627**, 193–203 (2017).
1269 109. R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D.
1270 Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J.
1271 Schneider, R. Ehmann, K. Zwirgmaier, C. Drosten, C. Wendtner, Virological assessment of
1272 hospitalized patients with COVID-2019, *Nature* **581**, 465–469 (2020).
1273 110. H. Bösmüller, S. Traxler, M. Bitzer, H. Häberle, W. Raiser, D. Nann, L. Frauenfeld, A.
1274 Vogelsberg, K. Klingel, F. Fend, The evolution of pulmonary pathology in fatal COVID-19
1275 disease: an autopsy study with clinical correlation, *Virchows Arch* **477**, 349–357 (2020).
1276 111. D. Szklarczyk, A. L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic,
1277 N. T. Doncheva, J. H. Morris, P. Bork, L. J. Jensen, C. von Mering, STRING v11: protein–
1278 protein association networks with increased coverage, supporting functional discovery in

- 1279 genome-wide experimental datasets, *Nucleic Acids Res* **47**, gky1131 (2018).
- 1280 112. G. Korotkevich, V. Sukhov, N. Budin, B. Shpak, M. N. Artyomov, A. Sergushichev, Fast
- 1281 gene set enrichment analysis, Biorxiv, 060012 (2021).
- 1282 113. S. Al-Benna, Association of high level gene expression of ACE2 in adipose tissue with
- 1283 mortality of COVID-19 infection in obese patients, *Obes Medicine* **19**, 100283 (2020).
- 1284 114. S. Gómez-Zorita, I. Milton-Laskibar, L. García-Arellano, M. González, M. P. Portillo, An
- 1285 Overview of Adipose Tissue ACE2 Modulation by Diet and Obesity. Potential Implications in
- 1286 COVID-19 Infection and Severity, *Int J Mol Sci* **22**, 7975 (2021).
- 1287 115. Z. Daniloski, T. X. Jordan, H.-H. Wessels, D. A. Hoagland, S. Kasela, M. Legut, S.
- 1288 Maniatis, E. P. Mimitou, L. Lu, E. Geller, O. Danziger, B. R. Rosenberg, H. Phatnani, P.
- 1289 Smibert, T. Lappalainen, B. R. tenOever, N. E. Sanjana, Identification of Required Host Factors
- 1290 for SARS-CoV-2 Infection in Human Cells, *Cell* **184**, 92-105.e16 (2021).
- 1291
- 1292 **Acknowledgements:** We thank the patients and their families for their consent to use their
- 1293 tissues. We would like to thank the Stanford Bariatric Surgery and Cardiothoracic Surgery clinic
- 1294 staff for assisting with participant recruitment and tissue harvesting. We thank Dr. Karin Klingel,
- 1295 Dr. Selina Traxler, Karen Greif, Dr. Massimo Granai and Dr. Hans Bösmüller (Department of
- 1296 Pathology, University Hospital Tübingen, Germany) for providing samples and logistic support.
- 1297 We would like to thank Anna Stalder and Jan Schneeberger (Institute of Medical Genetics and
- 1298 Pathology, University Hospital of Basel, Switzerland) for data analysis and technical assistance.
- 1299 We are thankful to Ralf Bartenschlager (University of Heidelberg, Germany) for providing
- 1300 A549-ACE2. The following reagent was deposited by the Centers for Disease Control and
- 1301 Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2,

1302 Isolate USA-WA1/2020, NR-52281. We thank Yael Rosenberg-Hasson, technical director of
1303 immunological assays at Stanford University's HIMC, for Luminex assays. We thank Jaishree
1304 Garhyan, director of Stanford's BSL3 service center, for BSL3 surveillance and training. We are
1305 grateful to Angela Detweiler and the Chan Zuckerberg Biohub foundation for sequencing.

1306

Funding:

1308 National Institutes of Health grant R21AI159024 (TLM)
1309 American Diabetes Association grant 7-20-COVID-213 (TLM)
1310 Stanford University Innovative Medicines Accelerator COVID-19 Response grant (CAB, TLM)
1311 Botnar Research Centre for Child Health grant Emergency Response to COVID-19 grant (SJ,
1312 CMS, KDM, AT, MSM, GPN)
1313 Swiss National Science Foundation grant 320030_189275 (MSM)
1314 Chan Zuckerberg Biohub Investigator Program (CAB)
1315 National Institutes of Health grant 5T32 AI007502 (AR)
1316 National Science Foundation Graduate Research Fellowship 2019282939 (KR)
1317 Bill and Melinda Gates Foundation OPP1113682 (JRA)
1318

Author contributions:

1320 Conceptualization: GMC, HeC, CAB, TLM
1321 Methodology: GMC, KR, HeC, SJ, HaC, CAB, TLM
1322 Investigation: GMC, KR, HeC, SZ, SJ, CMS, MSM, HaC, RV, AR
1323 Resources: EZ, DA, JB, AT, KDM, MSM, CMS, CAB, TLM
1324 Data Curation: GMC, KR, CAB, TLM

1325 Visualization: GMC, KR, SZ, SJ, CMS, MSM
 1326 Funding acquisition: CAB, TLM, SJ, CMS, AT, KDM, MSM, GPN
 1327 Supervision: JRA, GPN, CAB, TLM
 1328 Writing – original draft: GMC, KR, HeC, CAB, TLM
 1329 Writing – review & editing: GMC, KR, HeC, SJ, EZ, AR, RV, HaC, JRA, DA, JB, GPN, CMS,
 1330 MSM, CAB, TLM

1331

1332 **Competing interests:** CAB is on the Scientific Advisory Boards of Catamaran Bio and
 1333 DeepCell. CMS is on the Scientific Advisory Board of and has received research funding from
 1334 Enable Medicine, Inc., both outside the current work. MSM has served as a consultant for
 1335 Novartis and Glaxo Smith Kline and received speaker's honoraria from ThermoFisher and
 1336 Merck, all outside the current work.

1337

1338 **Data and materials availability:** Data from scRNA-seq will be deposited with the Gene
 1339 Expression Omnibus. A Github repository for all original code used for analysis and
 1340 visualization will be made public upon publication.

1341 **Figures**

1342 **Fig. 1. Exposure of stromal vascular cells (SVC) from adipose tissue to SARS-CoV-2**
 1343 **supports infection of macrophages.** (A) Sketch of workflow. SVC of human adipose tissue was
 1344 isolated by collagenase digestion prior to viral infection. SVC was infected or left untreated
 1345 (mock) with SARS-CoV-2 (USA-WA1/2020) at a multiplicity of infection (MOI) of 1. (B)
 1346 Relative gene expression of SARS-CoV-2 (N gene) obtained by 1-step RTqPCR at 24 hpi or
 1347 mock infection (SAT, n=6; VAT, n=4). (C) Relative gene expression of SARS-CoV-2 (N gene)

obtained by 1-step RTqPCR in cultures were treated with vehicle (DMSO) or 10 μ M remdesivir to inhibit viral replication and maintained for 24, 48, 72, and 96 hours before harvest. Relative expression was analyzed by $\Delta\Delta$ Ct method relative to a mock sample using 18S rRNA as a housekeeping gene. Each data point is an average of 3 technical replicates. (D) Frequency of SARS-CoV-2 infected cells based on SARS-CoV-2 N protein detection by flow cytometry of SAT (left, n=2) and VAT (right, n=2). Gating is detailed in supplemental figure 3. Statistical analysis: (A) paired, two-sided, student's t-test. **P<0.01, ***P<0.001. (B) Statistical analysis was performed with a two-way ANOVA, multiple comparisons using statistical hypothesis Sidak. *P<0.05. Data is presented as $\pm$ mean s.e.m. (A) Sketch was created with BioRender.

Fig. 2. A subset of macrophages is infected with SARS-CoV-2. (A) Schematic of experiment. The stromal vascular cells (SVC) were isolated from the SAT and VAT depots of three different participants and infected with either mock or SARS-CoV-2 (MOI of 1.0). Each sample was collected for scRNA-seq at 24 hpi. (B-C) UMAP representation of the SVC from all participants (n=3) across 198,759 cells, (B) colored by manually annotated cell type and (C) colored by infection and depot. (D) UMAP representation of all cells colored by SARS-CoV-2 cpm (log10). (E) Violin plot reveals the SARS-CoV-2 cpm values of all cells across SARS-CoV-2 infected samples, showing only the 8 cell clusters with the highest composition of SARS-CoV-2+ cells. Percentages above each cell type denote the percentage of cells within each cluster that have over 10 SARS-CoV-2 reads. (F) UMAP projections of all macrophages from the scRNA-seq dataset, colored by SARS-CoV-2 cpm (left), colored by CD68 expression (middle) and colored by ACE2 expression (right). (G) Dotplot of the proportion of cells (dot size) in the macrophage clusters split by infection condition expressing genes relevant for SARS-CoV-2 entry and antiviral defense, as well as SARS-CoV-2 cpm and macrophage cluster markers and colored by

1371 scaled average expression. (A) Sketch was created with BioRender.

1372 **Fig. 3. The infected macrophage cluster is marked by increased chemokine expression.** (A)

1373 Volcano plot of the differentially expressed genes between macrophage clusters 2 (C2) and 12

1374 (C12) across mock-infected samples. (B) Venn Diagram comparison of the significantly

1375 differentially expressed genes (DEGs) and their direction of change across C2 versus C12 in (1)

1376 mock-infected, (2) all SAT and (3) all VAT, and (4) SARS-CoV-2-infected conditions. (C)

1377 Heatmap of the most significant DEGs between SARS-CoV-2+ versus bystander macrophages

1378 within C2. (D) Normalized enrichment scores of top Reactome pathways, using significant

1379 DEGs between SARS-CoV-2+ versus bystander C2 macrophages.

1380 **Fig. 4. Preadipocytes respond to SARS-CoV-2 exposure.** (A,B) UMAP embedding of all

1381 preadipocytes (n=140,867) colored by (A) cluster and (B) sample and infection type. (C) Cell

1382 fraction bar plot clustered by sample and infection type within each cluster. (D) Feature plots

1383 depicting expression of selected markers associated with preadipocyte cell states, cell types and

1384 antiviral genes. (E) Box plots of average cytokine (top) and ISG- (bottom) module scores across

1385 the preadipocytes of each participant and depot in both mock and SARS-CoV-2 infection

1386 conditions. (F) Reactome pathway analysis was performed on the significant DEGs by

1387 participant and cluster within SAT. Pathways that were represented and significant in at least

1388 four of the participant-cluster subsets were included. Pathways clustered by Euclidean distance

1389 (tree not shown) and split by the two major subtrees.

1390 **Fig. 5. Mature and in vitro differentiated adipocytes support SARS-CoV-2 infection.**

1391 Mature adipocytes (MA) of human adipose tissue were isolated by collagenase digestion prior to

1392 viral infection. MA were infected or left untreated (mock) for 24 hours with SARS-COV-2

(USA-WA1/2020) at a MOI:1. (A) Measurements of genomic (gRNA) and subgenomic (sgRNA) SARS-CoV-2 genome copy numbers in infected MA from subcutaneous (left; n=3) and visceral (right; n=2 omentum; n=1 epicardial; n=1 pericardial) adipose tissue obtained by absolute gene quantification using 1-step RTqPCR TaqManTM and reported as fold change of infected to mock. (B) Relative gene expression of N gene in adipocytes differentiated in vitro from pericardial preadipocytes using adipocyte differentiation media for 0, 3, 6, and 13 days before left untreated or infected with SARS-CoV-2 at a MOI:1. Results were obtained by 1-step RTqPCR and analyzed by $\Delta\Delta C_t$ method using 18s as a housekeeping gene. (C) Adipocytes differentiated in vitro from preadipocytes obtained from pericardial adipose tissue were infected or mock infected with SARS-COV-2 (USA-WA1/2020) at a MOI of 1 for 1 hour, followed by washing and removing the virus and replacing with media treated with vehicle (DMSO) or 10 μ M remdesivir to inhibit viral replication. Cultures were maintained for 24, 48, 72, and 96 hpi, after which gene expression was obtained by 1-step RTqPCR for the N gene. Relative expression was analyzed by $\Delta\Delta C_t$ method relative to the mock sample. (C) Each data point is an average of 3 technical replicates and are presented as $\pm$ mean s.e.m.

Fig. 6. SARS-CoV-2 RNA and immune infiltration are present in adipose tissue of autopsy samples from COVID-19 patients. RNA in situ hybridization (ISH) on epicardial fat from heart autopsies from patients (Top, autopsy #9; Bottom, autopsy #10) who succumbed to COVID-19. Assays were performed using probes against SARS-CoV-2 Spike mRNA. Red arrowheads show ISH positive signals and blue arrows show inflammatory cells. (A and C) Overview of the heart tissue section (2mm), and (B and D) magnified view (20 μ m) of the represented region. (E) Interface of epicardial fat and myocardium (50 μ m). Note the inflammatory infiltration (blue arrows) only in the epicardial fat. Image has been rotated 90°.

Table 1. 80-plex Luminex analysis of stromal vascular cells from human adipose tissue exposed to SARS-CoV-2. Table summarizing results of 80-plex Luminex assay performed in supernatants of SVC (SAT, n=8; VAT, n=6) cultures that were infected with SARS-CoV-2 or mock-infected for 24 hours. First column shows analytes of interest. Second column categorizes analytes in either chemokine, growth factor, Th2 cytokine, inflammatory cytokine, cell adhesion molecule, or hematopoiesis regulatory cytokine. Columns 3 to 6 summarizes statistical results split by mean fold change and p and q (Adjusted p value) value obtained from Wilcoxon signed rank test. Columns 7 and 8 summarizes the known role of each analyte in COVID-19. Bottom of the table contains abbreviations and descriptions of statistics.

Table 2. Evidence of SARS-CoV-2 detection in adipose tissue from deceased individuals. Table summarizing SARS-CoV-2 PCR signals from 8 autopsy cases, seven of them from patients deceased from COVID-19. All threshold cycles (Ct) presented are an average of three SARS-CoV-2 gene sequences for open reading frame 1ab (ORF1ab), spike (S), and nucleocapsid (N). RNA was isolated from either epicardial, visceral, or subcutaneous fat. Heart RNA samples were collected from a mixture of myocardium and epicardium. Samples not presented in this study were marked as not available “N/A”. When the PCR signal was undetected, the sample was marked as “UD”.

SUPPLEMENTARY MATERIAL

Materials and Methods

Adipose Tissue Processing: Adipose tissue samples were minced and then digested by collagenase I (1 mg/mL) (Worthington Biochem. Corp, USA) at 37°C for 60 minutes, in KRBH

buffer containing BSA (2%), adenosine (250 uM), and P/S (1x), then filtered through a 500- μ m nylon mesh, followed by separation of MA and SVC. MA were utilized immediately; SVC was collected by centrifugation at 500 xg for 5 minutes at room temperature. The SVC pellet was incubated in erythrocyte lysis buffer (Invitrogen) for 10 minutes at 37°C, followed by centrifugation as above. The cell pellet was resuspended in HBSS (with 2% BSA) and centrifuged for another 5 minutes at 500 xg at RT. The SVC pellets were resuspended in growth medium (DMEM/F12, 10% FBS, and 1% P/S), filtered through a 75- μ m cell strainer, and cultured for expansion or immediate use.

Differentiation of human preadipocytes: As previously described (107), isolated SVC was expanded in DMEM/F12 containing FBS (10%) and P/S (1%), split to expand, and cultured until confluence. When cells reached 100% confluence, differentiation was induced using differentiation media, DM-2 (Zenbio, Inc) consisting of insulin, dexamethasone and isobutylmethylxanthine (IBMX) and pioglitazone supplemented with 10% FBS. After 3 days, the media was changed to adipocyte maintenance media, AM-1 (Zenbio, Inc) containing only insulin, dexamethasone in DMEM/F12 supplemented with 10% FBS (Fetal bovine serum). The cells were then left to differentiate for 3, 6, 12, and 14 days, with culture medium (AM-1) changed every 3 days. Day 0 preadipocytes were collected at time of confluence, just before adipogenesis induction. During differentiation, cells were collected at all the other time points and utilized immediately for experiments as described. Adipogenesis was confirmed by oil droplet formation and by increased expression of fatty acid-binding protein 4 gene, Fabp4.

SARS-CoV-2 infections of differentiated adipocytes, SVC, and A549-ACE2: Cells were seeded a day before infection by culturing 4×10^5 - 1×10^6 cells per well in a 6-well plate (Corning). On the day of infection, SVC was centrifuged at 500g for 5mins, and washed with infection media (DMEM, 2%FBS, and 1% Pen-strep). Adherent differentiated adipocytes and A549-ACE2 were washed with infection media. A549-ACE2 cells were cultured under the presence of 623µg/ml of Geneticin (Thermo Fisher Scientific; 10121035) for selection of ACE2 expressing cells. Viral infection was performed with SARS-CoV-2 (2019-nCoV/USA-WA1/2020) at a MOI of 1 for 1 hour while gently rocking before cells were washed and culture in culture media (DMEM, 10%FBS, and 1% Pen-strep) at 37°C with 5%CO₂ under BSL3 containment. When remdesivir was used, cells were subjected to multiple washes with PBS 1 hour after infection before culturing under the presence of vehicle, dimethylsulfoxide (DMSO) (Sigma; D2650), or 10µM Remdesivir (Gilead) in DMSO and cultured for longer periods (24, 48, 72, and 96hpi).

SARS-CoV-2 infections of MA: MA media was changed into infection media by penetrating the fat tissue with a 22-gauge polytetrafluoroethylene (PTFE) (Grainger) blunt needle attached to a 3cc syringe (Grainger), or by gently transferring the fat with a wide manually cut p100 tip into a 5ml conical collection tube containing 2mls of warm media. Viral infection was performed with the WA/01 strain of SARS-COV-2 (2019-nCoV/USA-WA1/2020) at a multiplicity of infection (MOI) of 1 by gently adding virus to the top of the floating cells under BSL3 containment. MA was incubated for 1 hour while gently rocking at 37°C with 5%CO₂. Media was then removed using as mentioned above prior to adding culture media (DMEM, 10%FBS, and 1% Pen-strep) and incubating at 37°C with 5%CO₂.

Flow Cytometry: Cells were collected using Trypsin-EDTA (Thermo Scientific, 25200072) for 5-10mins at 37°C and 5% CO₂. Cells were then centrifuged, 500g for 5 minutes, and washed with PBS (Thermo Scientific, 10010023) and transferred into a 96-well plate, then washed twice more with FACS buffer (PBS, 2%FBS (Corning, MT35016CV), and 5mM EDTA (Hoefer, GR123)). Cells were incubated in Zombie aqua cell viability dye (BioLegend, 423102) at room temperature for 20 minutes, washed twice, incubated at room temperature with Fc block (BioLegend, 422302) for 5 minutes, and surface stained for 30 minutes at 4°C. Surface staining contained antibodies for CD45 (BioLegend, 368503), CD3 (BioLegend, 317343), CD14 (BioLegend,301835), CD19 (BioLegend, 302261), CD11c (BioLegend, 371503), CD34 (BioLegend, 343615), CD31 (BioLegend, 303133). In fig. S4, surface staining also contained antibodies against ACE2 (R&D, fab9332r) or isotype control (R&D, ICOO3R). After surface staining, cells were washed twice with FACS buffer before fixation with 4% Paraformaldehyde (PFA) (Electron Microscopy Sciences, 15710) for 1 hour at 4°C, cells were then permeabilized (eBioscience, 00-8333-56) for 10 minutes at room temperature before intracellular staining for 45 minutes at 4°C. Intracellular staining contained an anti-SARS-CoV-2 N protein antibody (Sino Biological, 40143-T62). After intracellular staining, cells were washed with PBS, and diluted in 1%PFA and PBS before analyzing in a Cytex™ Aurora. FCS files were collected and analyzed using FlowJo™. Gating was done as shown in Fig. 1A.

1-step RTqPCR for relative gene quantification: RNA was then mixed with TaqPath 1-step RTqPCR master mix (Applied Biosystems, A15299) and primers for SARS-CoV-2 *N-gene* (Biosearch technologies; n2019-nCoV KIT-NCOV-PP1-1000), *IL-6* (Thermo scientific, Hs00174131_m1), *IFNA1* (Thermo scientific, Hs04189288_g1), *IFNB1* (Thermo scientific,

1506 Hs01077958_s1), *ISG15* (Thermo scientific, Hs01921425_s1), *IFI27* (Thermo Scientific,
1507 Hs01086373_g1), and *IER3* (Thermo scientific, Hs00174674_m1) for relative gene
1508 quantification. Relative expression was calculated by obtaining $\Delta\Delta CT$, using the endogenous
1509 control eukaryotic 18S rRNA (Thermo Scientific, 4352930E) and mock samples as the calibrator
1510 control. The samples were analyzed on a QuantStudio™ 3 (Applied Biosystems) with the
1511 following parameters: 2 minutes at 25°C for uracil-DNA glycosylase (UNG) incubation, 15
1512 minutes at 50°C for RT, 2 minutes at 95°C for polymerase activation, and 40 cycles of 15
1513 seconds at 95°C and 30 seconds of 60°C for amplification.

1514
1515 **2-step RTqPCR for *ACE2*, *Fabp4*, and *18s*:** RT on isolated RNA was performed with
1516 Superscript III first-strand synthesis system (Thermo scientific, 18080051). For qPCR, <100ng
1517 of cDNA were mixed with designed reverse and forward primers and PowerUp SYBR green
1518 master mix (Applied biosystems, A25742). The samples were analyzed on a QuantStudio™ 3
1519 (Applied Biosystems) with the following parameters: 10 minutes at 95°C for polymerase
1520 activation, and 40 cycles of 15 seconds at 95°C and 60 seconds of 60°C for amplification. The
1521 designed primers were the following: *ACE2* forward (TAACCACGAAGCCGAAGACC) and
1522 reverse (TTGGGCAAGTGTGGACTGTT), *Fabp4* forward (TGGGCCAGGAATTTGACGAA),
1523 and reverse (CACATGTACCAGGACACCCC); *18s* forward
1524 (GGCCCTGTAATTGGAATGAGTC) and reverse (CCAAGATCCAACACTACGAGCTT). All
1525 primers were designed with mRNA sequence using National Center for Biotechnology
1526 Information primer designing tool, Primer-BLAST. All sequences are Sequence 5'→3'.

1527

RNA-ISH: For deparaffinization, slides were baked at 70 °C for 1 hour in a temperature-controlled oven, then immersed in fresh xylene twice for 5 minutes each. Rehydration was performed using a Leica ST4020 Linear Stainer (Leica Biosystems) programmed to three dips per wash for 180 seconds each with the following buffers: xylene x 3, 100% ethanol x 2, 95% ethanol x 2, 80% ethanol x 1, 70% ethanol x 1, and ddH₂O x 3. Heat induced epitope retrieval was subsequently performed in a Lab Vision PT module (Thermo Fisher) using the Dako Target Retrieval Solution, pH 9 (DAKO Agilent, S236784-2) at 97 °C for 10 minutes, followed by controlled cooling down to 65 °C. Slides were removed from the PT module and further cooled to room temperature for 30 minutes before rinsing briefly in sterile, nuclease-free water (ddH₂O) twice. A 15 minutes hydrogen peroxide block was subsequently performed at 40 °C (Bio-Techne, 322335). Slides were then washed twice for 2 minutes each in ddH₂O before an overnight hybridization at 40 °C with probes against the SARS-CoV-2 Spike mRNA (Bio-Techne, 848561). Amplification of the ISH probes was performed the next day according to the manufacturer's protocol (Bio-Techne, 322350). Slides were then dried, mounted, and subsequently scanned via an Aperio slide scanner at the Stanford School of Medicine Histology Core.